Molecular Medicine Program Metrics

View the clinical trials, grants and publications from the Cancer Epidemiology Program.

Clinical Trials
CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable ()

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib (); Not Applicable (); Placebo (); Xalkori (Crizotinib)

CLINICAL TRIAL 18304
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Condition: Thoracic
Intervention: AZD1775 (); MK-1775 (AZD1775); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()

CLINICAL TRIAL 18494
A Phase I/II Study of Pembrolizumab and Vorinostat in Patients with Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Vorinostat (); Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)

CLINICAL TRIAL 18741
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A Phase 3 Randomized Multicenter Trial to Compare Hepatic Progression-Free Survival Following Bland Embolization, Lipiodol Chemoembolization, and Drug-Eluting Bead Chemoembolization of Neuroendocrine Liver Metastases
Condition: Gastrointestinal Tumor
Intervention: Adriamycin (doxorubicin); Not Applicable (); doxorubicin ()

CLINICAL TRIAL 18778
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Condition: Neurologic Oncology
Intervention: Lomustine (CeeNU); eflornithine ()

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); TSR-022 (); TSR-033 (); TSR-042 (Dostarlimab); Taxotere (docetaxel); docetaxel ()

CLINICAL TRIAL 18926
The National Myelodysplastic Syndromes (MDS) Study
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 18959
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Condition: Gynecological Tumor
Intervention: Fluconazole (); IL-2 (Interleukin-2); LN-145 (); MESNA (); Neupogen (filgrastim); Pembrolizumab (Keytruda); cyclophosphamide (); cytoxan (cyclophosphamide); filgrastim (); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 18989
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: PV-10 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 19072
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 19137
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
Condition: Genitourinary
Intervention: Abiraterone acetate (); Olaparib (Lynparza); Zytiga (Abiraterone acetate); prednisone ()

CLINICAL TRIAL 19327
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 19207
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
Condition: Gastrointestinal Tumor
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); Pembrolizumab (Keytruda)

CLINICAL TRIAL 19322
A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Hematological Malignancies
Condition: Malignant Hematology
Intervention: Hu5F9-G4 (); azacitidine (5-azacitidine)

CLINICAL TRIAL 19342
A Phase I Trial of Pembrolizumab and Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
Condition: Neurologic Oncology
Intervention: Pembrolizumab (Keytruda); SAHA (Vorinostat); Temodal (Temozolomide); Temozolomide (); Vorinostat (); Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)

CLINICAL TRIAL 19360
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM)
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); Daratumumab (Darzalex); Dexamethasone (); Lenalidomide (Revlimid); carfilzomib (Kyprolis)

CLINICAL TRIAL 19379
A Phase 2, Multicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Luspatercept (Ace-536) In Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia With And Without Red Blood Cell-Transfusion Dependence
Condition: Malignant Hematology
Intervention: ACE-536 (Luspatercept); Luspatercept ()

CLINICAL TRIAL 19387
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Condition: Thoracic
Intervention: Poziotinib ()

CLINICAL TRIAL 19389
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: JNJ-61186372 (Amivantamab)

CLINICAL TRIAL 19406
Phase I/II Study of Nivolumab and Ipilimumab combined with Nintedanib in Non Small Cell Lung Cancer
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nintedanib (); Nivolumab (Opdivo); Yervoy (Ipilimumab)

CLINICAL TRIAL 19407
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage IIIB/C Melanoma Patients
Condition: Cutaneous
Intervention: Daromun (); Not Applicable ()

CLINICAL TRIAL 19428
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: Bortezomib (); Daratumumab (Darzalex); Dexamethasone (); GDC-0199 (Venetoclax); PS-341 (Bortezomib); Velcade (Bortezomib); Venetoclax ()

CLINICAL TRIAL 19441
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Binimetinib (); Cobimetinib (); Encorafenib (); Nivolumab (Opdivo); Not Applicable (); RO5185426 (Vemurafenib); Vemurafenib (Zelboraf)

CLINICAL TRIAL 19462
An Open-Label, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors and Lymphomas
Condition: Multiple
Intervention: Bay 1895344 ()

CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Bempegaldesleukin (Nktr-214) And In combination With Bempegaldesleukin (Nktr-214) Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); NKTR-214 (Bempegaldesleukin); NKTR-262 (); Nivolumab (Opdivo)

CLINICAL TRIAL 19475
Phase 1 Study of Trametinib + Ceritinib in Patients with Unresectable Melanoma
Condition: Cutaneous
Intervention: Ceritinib (Zykadia); GSK1120212 (Trametinib); Trametinib ()

CLINICAL TRIAL 19495
A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases
Condition: Cutaneous
Intervention: Avelumab (); MSB00100718C (Avelumab); Placebo ()

CLINICAL TRIAL 19570
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients with RM SCCHN
Condition: Head & Neck
Intervention: Cabozantinib (XL 184); Pembrolizumab (Keytruda)

CLINICAL TRIAL 19635
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) who had Disease Progression or are Intolerant to Prior Therapy
Condition: Malignant Hematology
Intervention: LB-100 ()

CLINICAL TRIAL 19648
Phase IB Study of Avelumab with Radiotherapy in Patients with Leptomeningeal Disease
Condition: Neurologic Oncology
Intervention: Avelumab (); MSB00100718C (Avelumab)

CLINICAL TRIAL 19656
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Condition: Thoracic
Intervention: Ceritinib (Zykadia); Taxotere (docetaxel); docetaxel ()

CLINICAL TRIAL 19658
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
Condition: Malignant Hematology
Intervention: SX-682 ()

CLINICAL TRIAL 19683
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors
Condition: Thoracic
Intervention: RMC-4630 ()

CLINICAL TRIAL 19692
A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide Compared to Targeted Molecular Therapy with Everolimus in Patients with Inoperable, Progressive, Somato-Statin Receptor-Positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)
Condition: Gastrointestinal Tumor
Intervention: 177Lu-edotreotide (); everolimus (RAD001)

CLINICAL TRIAL 19684
A Phase I/Ib, Open-Label, Multi-Center Study of NZV930 as a Single Agent and in Combination with PDR001 and/or NIR178 in Patients with Advanced Malignancies
Condition: Thoracic
Intervention: NIR178 (); NZV930 (); PDR001 (Spartalizumab)

CLINICAL TRIAL 19694
Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); IMC-1121B (Ramucirumab); Nivolumab (Opdivo); Ramucirumab ()

CLINICAL TRIAL 19715
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma
Condition: Malignant Hematology
Intervention: Bendamustine (); Mosunetuzumab (); Polatuzumab Vedotin (); Rituxan (rituximab); Tocilizumab (); rituximab ()

CLINICAL TRIAL 19722
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Condition: Malignant Hematology
Intervention: bb2121 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 19708
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
Condition: Cutaneous
Intervention: Pramlintide ()

CLINICAL TRIAL 19872
A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (Ace-536) Versus Epoetin Alfa for the Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (Mds) In Esa Naïve Subjects Who Require Red Blood Cell Transfusions The Commands Trial
Condition: Malignant Hematology
Intervention: ACE-536 (Luspatercept); Epoetin Alfa (erythropoietin); Luspatercept (); Not Applicable ()

CLINICAL TRIAL 19732
Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (Cabinet)
Condition: Gastrointestinal Tumor
Intervention: Cabozantinib (XL 184); Placebo ()

CLINICAL TRIAL 19956
A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Condition: Neurologic Oncology
Intervention: CB-839 (Telaglenestat); Temodal (Temozolomide); Temozolomide ()

CLINICAL TRIAL 19819
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Condition: Head & Neck
Intervention: Paraplatin (carboplatin); Taxotere (docetaxel); carboplatin (); cisplatin (); docetaxel ()

CLINICAL TRIAL 19754
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); NKTR-214 (Bempegaldesleukin); Nivolumab (Opdivo)

CLINICAL TRIAL 19776
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3021 ()

CLINICAL TRIAL 19820
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: INCB086550 ()

CLINICAL TRIAL 19855
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma(HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
Condition: Head & Neck
Intervention: Zarnestra (tipifarnib); tipifarnib ()

CLINICAL TRIAL 19862
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: PRGN-3006 T Cell (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 19958
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only)
Condition: Cutaneous
Intervention: ABT-263 (Navitoclax); GSK1120212 (Trametinib); GSK2118436 (dabrafenib); Navitoclax (); Trametinib (); dabrafenib ()

CLINICAL TRIAL 19940
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Plinabulin (); Yervoy (Ipilimumab)

CLINICAL TRIAL 19942
Sequential Maintenance with Thoracic Radiotherapy and Durvalumab (MEDI4736) monotherapy or Durvalumab (MEDI 4736) combinations (Tremelimumab or Olaparib) in patients with Extensive Stage-Small Cell Lung Cancer after first line Platinum-based Chemotherapy
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); CP-675,206 (tremelimumab); Durvalumab (); MEDI4736 (Durvalumab); Olaparib (Lynparza); tremelimumab ()

CLINICAL TRIAL 19948
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); Cobimetinib ()

CLINICAL TRIAL 19943
Somatostatin receptor expression in poorly-differentiated neuroendocrine carcinomas of the GI tract: analysis using 68Ga-dotatate PET scan
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 19970
A Pilot Trial of Intratumorally-Administered Topotecan using Convection-Enhanced Delivery (CED) in Patients with Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)
Condition: Neurologic Oncology
Intervention: Topotecan ()

CLINICAL TRIAL 19967
A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma
Condition: Cutaneous
Intervention: CX-4945 ()

CLINICAL TRIAL 20003
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer(Lung-MAP Screening Study)
Condition: Thoracic
Intervention: AG-014447 (Rucaparib); Alimta (Pemetrexed); Avelumab (); BMN-673 (Talazoparib); CO-338 (Rucaparib); Gemzar (gemcitabine); IMC-1121B (Ramucirumab); MSB00100718C (Avelumab); PF-01367338-BW (Rucaparib); Pembrolizumab (Keytruda); Pemetrexed (); Ramucirumab (); Rucaparib (); Selpercatinib (); Talazoparib (); Taxotere (docetaxel); docetaxel (); gemcitabine ()

CLINICAL TRIAL 19981
A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); CYT107 ()

CLINICAL TRIAL 19988
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Condition: Genitourinary
Intervention: IMMU-132 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20015
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab ()

CLINICAL TRIAL 20038
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: CB-839 (Telaglenestat); Dexamethasone (); carfilzomib (Kyprolis)

CLINICAL TRIAL 20040
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda)

CLINICAL TRIAL 20061
A Pilot Study of CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: CPX-351 (Vyxeos)

CLINICAL TRIAL 20114
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients with Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Condition: Head & Neck
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20069
A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination with Rituximab in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) and Indolent Non-Hodgkin Lymphoma (R/R iNHL)
Condition: Malignant Hematology
Intervention: CC-99282 (); Rituxan (rituximab); rituximab ()

CLINICAL TRIAL 20078
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Condition: Thoracic
Intervention: Pembrolizumab (Keytruda); Placebo ()

CLINICAL TRIAL 20110
GBM Agile: Global Adaptive Trial Master Protocol
Condition: Neurologic Oncology
Intervention: BAY 73-4506 (Regorafenib); Lomustine (CeeNU); Regorafenib (Stivarga); Temodal (Temozolomide); Temozolomide ()

CLINICAL TRIAL 20099
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Nab-paclitaxel (Abraxane); Olaparib (Lynparza); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Placebo (); Taxol (paclitaxel); carboplatin (); paclitaxel ()

CLINICAL TRIAL 20145
A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 using Convection-enhanced Delivery in Patients with Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection
Condition: Neurologic Oncology
Intervention: OS2966 ()

CLINICAL TRIAL 20144
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Head & Neck
Intervention: CUE-101 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20162
Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 ()

CLINICAL TRIAL 20168
HORMONET: Phase II Study of Hormone Therapy with Tamoxifen in Patients with well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Condition: Gastrointestinal Tumor
Intervention: Tamoxifen ()

CLINICAL TRIAL 20174
A Phase I, Open-Label, Dose Finding Study To Assess The Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy Of OBT076, A CD205-Directed Antibody-Drug Conjugate, In Recurrent And/Or Metastatic CD205 Positive Solid Tumors And In Women With CD205 Positive HER2-Negative Metastatic Breast Cancer
Condition: Multiple
Intervention: OBT076 ()

CLINICAL TRIAL 20178
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); IMC-1121B (Ramucirumab); Osimertinib (); Ramucirumab ()

CLINICAL TRIAL 20256
CemiplimAb Survivorship Epidemiology (CASE) Study
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20187
Development of Intra-tumor Driver Mutation Prevalence as a Predictor of Efficacy of Targeted Agents
Condition: Gynecological Tumor
Intervention:

CLINICAL TRIAL 20254
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naive
Condition: Cutaneous
Intervention: Avelumab (); KRT-232 (); MSB00100718C (Avelumab)

CLINICAL TRIAL 20292
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
Condition: Malignant Hematology
Intervention: SNDX-5613 ()

CLINICAL TRIAL 20266
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Condition: Malignant Hematology
Intervention: TTI-621 ()

CLINICAL TRIAL 20286
A Phase III Multi-Center, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET
Condition: Gastrointestinal Tumor
Intervention: 177Lu-DOTA0-Ty3-Octreotate (Lutathera); Lutathera (); octreotide LAR ()

CLINICAL TRIAL 20297
Cabozantinib plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Condition: Genitourinary
Intervention: Cabozantinib (XL 184); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20304
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (Codebreak 100)
Condition: Thoracic
Intervention: AMG 510 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20313
Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Tavo-EP ()

CLINICAL TRIAL 20332
Activity and Enhancement of Immune Checkpoint Inhibition with Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)
Condition: Thoracic
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); PM01183 (lurbinectedin); Yervoy (Ipilimumab); lurbinectedin ()

CLINICAL TRIAL 20347
A phase 2 basket trial of glutaminase inhibitor (BeGIN) CB-839 HCl in patients with NF1 Aberrations, NF1 mutant malignant peripheral nerve sheath tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant tumors
Condition: Sarcoma
Intervention: CB-839 HCl ()

CLINICAL TRIAL 20419
Phase II Study of Short Course FOLFOX Chemotherapy with Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Condition: Gastrointestinal Tumor
Intervention: BMS-936558 (Nivolumab); FOLFOX (); Nivolumab (Opdivo)

CLINICAL TRIAL 20364
A Phase 1/2 Study of REGN5093 in Patients with Met-Altered Advanced Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: REGN5093 ()

CLINICAL TRIAL 20349
A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
Condition: Breast
Intervention: Faslodex (fulvestrant); TAS-120 (); fulvestrant ()

CLINICAL TRIAL 20373
TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()

CLINICAL TRIAL 20413
Phase III Study Of Daratumumab/Rhuph20 (Nsc- 810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC STUDY)
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); Daratumumab/rHuPH20 (); Lenalidomide (Revlimid)

CLINICAL TRIAL 20375
Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Condition: Malignant Hematology
Intervention: APR-246 (); GDC-0199 (Venetoclax); Venetoclax (); azacitidine (5-azacitidine)

CLINICAL TRIAL 20402
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Nivolumab (Opdivo); Paraplatin (carboplatin); Pemetrexed (); Placebo (); Taxol (paclitaxel); Taxotere (docetaxel); carboplatin (); cisplatin (); docetaxel (); paclitaxel ()

CLINICAL TRIAL 20520
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer
Condition: Immunotherapy
Intervention: AMG 757 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 50337
Optimization of High-Grade Glioma Tissue Dissociation for the Maintenance of Cell Viability
Condition: Neurologic Oncology
Intervention:

CLINICAL TRIAL 20474
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
Condition: Thoracic
Intervention: XMT-1536 ()

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20497
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability and Efficacy of MORAb-202, a Folate Receptor Alpha (FRA)-Targeting Antibody-Drug Conjugate (ADC) in Subjects with Selected Tumor Types
Condition: Gynecological Tumor
Intervention: MORAb-202 ()

CLINICAL TRIAL 20530
Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20561
Randomized Trial of Prolonged Use of Negative Pressure Wound Therapy in Patients Undergoing Surgical Procedures for the Management of Gastrointestinal Malignancies
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 20528
Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20552
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab with Darbepoetin alfa in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) who have Failed Erythropoietin Stimulating Agents (ESA)
Condition: Malignant Hematology
Intervention: Canakinumab (); Darbepoetin alfa ()

CLINICAL TRIAL 20557
A Phase II, Open-Label, Multicenter, Randomized Study of Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 20562
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); RP1 ()

CLINICAL TRIAL 20577
A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors with Specific Genomic Aberrations
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); Cobimetinib (); Osimertinib (); RMC-4630 ()

CLINICAL TRIAL 20634
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV)Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
Condition: Malignant Hematology
Intervention: Danazol (); Momelotinib (); Momelotinib/Danazol/Placebo ()

CLINICAL TRIAL 20605
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Cofetuzumab Pelidotin ()

CLINICAL TRIAL 20600
A Phase I, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients with Advanced Solid Tumors and Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Jakafi (Ruxolitinib); PRT543 (); Ruxolitinib ()

CLINICAL TRIAL 20619
A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated with Deleterious Mutations in Homologous Recombination Repair Genes (LODESTAR)
Condition: Multiple
Intervention: AG-014447 (Rucaparib); CO-338 (Rucaparib); Not Applicable (); PF-01367338-BW (Rucaparib); Rucaparib ()

CLINICAL TRIAL 20628
A Phase II, Open-Label, Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progressive Metastatic Castrate-Resistant Prostate Cancer (AARDVARC)
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); AZD4635 (); Cabazitaxel (); Durvalumab (); Jevtana (Cabazitaxel); MEDI4736 (Durvalumab)

CLINICAL TRIAL 20641
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Binimetinib (); Encorafenib (); Nivolumab (Opdivo); Not Applicable ()

CLINICAL TRIAL 20749
A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: CA-4948 ()

CLINICAL TRIAL 20716
ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: Magrolimab/Placebo (); azacitidine (5-azacitidine)

CLINICAL TRIAL 20734
Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT)
Condition: Breast
Intervention:

CLINICAL TRIAL 20753
An Open-Label Phase I, Multi-Center Study to Determine the Recommended Dose of the Chimeric Antigen Receptor T-cell Treatment CYAD-211 After a Non-Myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients with Relapsed or Refractory Disease (IMMUNICY-1)
Condition: Multiple Myeloma
Intervention: CYAD-211 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20748
TENACITY- A Phase 2, Multicenter, Open-Label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer
Condition: Breast
Intervention: AL101 (); BMS-906024 (AL101)

CLINICAL TRIAL 20773
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20767
Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()

CLINICAL TRIAL 20772
An Open-label Phase 1b/2a Study of NT-I7 (Hyleukin-7) in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Advanced Solid Tumors
Condition: Multiple
Intervention: NT-I7 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20763
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20769
A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); Alimta (Pemetrexed); Osimertinib (); Paraplatin (carboplatin); Pemetrexed (); carboplatin (); cisplatin ()

CLINICAL TRIAL 20782
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Condition: Thoracic
Intervention: Seribantumab ()

CLINICAL TRIAL 20839
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); NKTR-214 (Bempegaldesleukin); Nivolumab (Opdivo)

CLINICAL TRIAL 20825
A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Condition: Gastrointestinal Tumor
Intervention: RLY-4008 ()

CLINICAL TRIAL 20883
A Phase 1 Study of MLN4924 (pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Condition: Malignant Hematology
Intervention: Belinostat (); MLN4924 (Pevonedistat); PXD101 (Belinostat)

CLINICAL TRIAL 20830
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Telaglenastat/Placebo (); carboplatin ()

CLINICAL TRIAL 20885
A Phase 2 Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Condition: Gastrointestinal Tumor
Intervention: BMS-936558 (Nivolumab); Cabozantinib (XL 184); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)

CLINICAL TRIAL 20898
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
Condition: Genitourinary
Intervention: Ceralasertib ()

CLINICAL TRIAL 20866
A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Enfortumab Vedotin (Padcev); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Sitravatinib ()

CLINICAL TRIAL 20904
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in Braf-V600 Mutant Melanoma with Brain Metastases
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Binimetinib (); Encorafenib (); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)

CLINICAL TRIAL 20893
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess the Efficacy and Safety of Multiple LXH254 Combinations in Patients with Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Condition: Cutaneous
Intervention: GSK1120212 (Trametinib); LEE011 (Ribociclib); LTT462 (); LXH254 (); Ribociclib (); Trametinib ()

CLINICAL TRIAL 20943
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sacituzumab Govitecan (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21065
Tumor Stroma in Pancreatic Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 21129
A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors
Condition: Multiple
Intervention: RMC-5552 ()

CLINICAL TRIAL 21214
Association of Gender with Adverse Events, Prescribing Patterns and Oncologic outcomes in Patients being treated with Immuno-Oncology Agents
Condition: Cutaneous
Intervention:

Grants
  • Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement
    Sponsor: Nat Institutes of Health
    PI (Contact):Cleveland, J.,PI:Eroglu, Z.
  • Development of Educational Materials and Educational Guidance Related to Limb/Hepatic Perfusion of Chemotherapy
    Sponsor: Delcath Systems, Inc.
    PI:Zager, J.
  • Harnessing Beneficial Off-Target Effects of Kinase Inhibitors in Lung Cancer
    Sponsor: Nat Institutes of Health
    PI:Rix, U.
  • The Role of EGFR as a Mechanism of Therapeutic Resistance in Gene Fusion Positive Lung Cancer
    Sponsor: Univ of Colorado
    PI:Haura, E.
  • Validation of EGFR Protein Complexes as Molecular Diagnostics
    Sponsor: Nat Institutes of Health
    PI:Haura, E.
  • Quantitative Fe-MRI Analysis and Creation of Fe-Agar Phantom Tube Sets and Manual Consultancy
    Sponsor: Imaging Endpoints
    PI:Raghunand, N.
  • Phase II Trial Evaluating the use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
    Sponsor: Novartis Pharmaceuticals Corp.
    PI:Perez, L.
  • Piloting the Feasibility of 11C-AMT PET Imaging in Recurrent High Grade Glioma Patients Treated on Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined with Nivolumab
    Sponsor: Moffitt Cancer Center
    PI:Sahebjam, S.,CO-PI:Tian, H.
  • Precision Lung Cancer Therapy Design Through Multiplexed Adapter Measurement
    Sponsor: Nat Institutes of Health
    PI (MPI):Haura, E.
  • CPTAC Phase III
    Sponsor: Nat Institutes of Health
    PI:Koomen, J.
  • Molecular Signatures of Immunotherapy Response and Improved Survival in Tobacco-Related Head and Neck Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Chung, C.
  • Targeting Bidirectional Signaling in Lung Stroma and Cancer Stems
    Sponsor: Nat Institutes of Health
    PI (Contact):Rix, U.,PI (MPI):Haura, E.
  • The Design of Novel Stable, Strained Diazirines for Fuctionalization in Organic Synthesis
    Sponsor: Amer Chemical Society
    PI:Lopchuk, J.
  • Ubiquitination-dependent Regulation of BRAF Function in Melanoma
    Sponsor: Amer Cancer Society
    PI:Wan, L.
  • Genomic Based Personalization of Radiotherapy for Retroperitoneal Sarcoma
    Sponsor: Moffitt Cancer Center
    PI:Naghavi, A.
  • New Therapeutic Vulnerabilities for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)
    Sponsor: Lymphoma Research Fdtn
    PI:Tao, J.
  • Defining Impact of HDAC Inhibitors on Tumor Immunogenicity, T Cell Functionality and PD-1 Blockade Response in NSCLC Patients
    Sponsor: US Army
    PI:Gray, J.
  • Targeting the JNK-ITCH Signaling Pathway in Melanoma
    Sponsor: Melanoma Research Alliance (MRA)
    PI:Wan, L.
  • Reprogramming Transmembrane ubiquitin Ligases To Control Cell Surface Receptor Landscapes.
    Sponsor: Rita Allen Foundation
    PI:Luca, V.
  • Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia
    Sponsor: Nat Institutes of Health
    PI:Padron, E.
  • Epigenetic Regulation of Drug Resistance to ABT-199 in B-cell Malignancies
    Sponsor: Nat Institutes of Health
    PI:Tao, J.
  • Center for Immunotherapeutic Transport Oncophysics PSOC-Project 2
    Sponsor: Nat Institutes of Health
    PI:Fleming, J.
  • Transcriptional and Epigenetic Adaptation as Novel Therapeutic Vulnerabilities for Mantle Cell Lymphoma
    Sponsor: Nat Institutes of Health
    PI (MPI):Tao, J.
  • Cytokine-dependent Genetic Selection in Chronic Myelomonocytic Leukemia
    Sponsor: Amer Cancer Society
    PI:Padron, E.
  • Prognostic Significance of Serial Molecular Annotation in Secondary Acute Myeloid Leukemia (sAML) in Patients Treated with CPX-351
    Sponsor: Jazz Pharmaceuticals
    PI:Sallman, D.
  • Determine if Subtypes of CMML Segregated by RAS Pathway Mutations are Differentially Sensitive to Tipifamib in vitro (phase 1) in vivo (phase 2)
    Sponsor: Kura Oncology, Inc.
    PI:Padron, E.
  • Tumor Suppressor Role of TFEB in MYC-driven Myeloid Leukemogenesis
    Sponsor: Amer Society of Hematology
    PI:Yun, S.
  • An International Working Group for the Integration of Molecular Data in CMML
    Sponsor: Celgene Corp.
    PI:Padron, E.
  • Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering
    Sponsor: Nat Institutes of Health
    PI:Luca, V.
  • Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation
    Sponsor: Nat Institutes of Health
    PI:Lau, E.
  • Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation
    Sponsor: Nat Institutes of Health
    PI:Lau, E.
  • New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
    Sponsor: Nat Institutes of Health
    PI (Contact):Tao, J.,PI (MPI):Cleveland, J.
  • Novel Methods for Radical and Electrophilic Amination
    Sponsor: Nat Science Foundation
    PI:Lopchuk, J.
  • Defining and modeling pediatric melanoma development
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Smalley, K.
  • A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Druta, M.
  • Development of novel TAF1 inhibitors as cancer therapeutics
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Schonbrunn, E.,CO-PI:Chen, J.,CO-PI:Lopchuk, J.
  • Allosteric CDK2 Inhibitor Discovery and Development for Male Contraception
    Sponsor: Nat Institutes of Health
    PI:Schonbrunn, E.
  • Targeted Inhibition in Stromal TGF Beta Activity in Pancreatic Cancer
    Sponsor: Nat Institutes of Health
    PI:Fleming, J.
  • Therapeutic Targeting of Casein Kinase-1-delta in Primary Metastatic Breast Cancer
    Sponsor: Nat Institutes of Health
    PI (Contact):Duckett, D.,PI (MPI):Cleveland, J.
  • Development of in vivo active small molecule activators of Ulk1
    Sponsor: Nat Institutes of Health
    PI (Contact):Duckett, D.
  • Development of New Casein Kinase 1 Inhibitor for the Treatment of BrainCancers
    Sponsor: Nat Institutes of Health
    PI:Duckett, D.
  • A Phase 2 Study of TRC 105 in Combination with Pazopanib in Patients with AdvancedLeiomyosarcoma (Uterine and Non-uterine LMS}: an Investigator Initiated Study
    Sponsor: National Leiomyosarcoma Foundation
    PI:Druta, M.
  • Novel First in Class Drug Combination for the Treatment of Acute Myeloid Leukemia
    Sponsor: Moffitt Cancer Center
    PI:Lancet, J.
  • Improving the understanding and diagnosis of leptomeningeal lymphoma metastasis
    Sponsor: Moffitt Cancer Center
    PI:Smalley, I.,CO-PI:Sokol, L.
  • MEG3 as a therapeutically relevant target for TET2 mutant myeloid neoplasms
    Sponsor: Moffitt Cancer Center
    PI:Padron, E.
  • Sequential Maintenance with Thoracic Radiotherapy and Durvalumab MEDI4736 monotherapy or Durvalumab MEDI 4736 combinations Tremelimumab or Olaparib
    Sponsor: AstraZeneca Pharmaceuticals, LP
    PI:Chiappori, A.
  • Structure-guided engineering of Lag3 immunomodulatory function
    Sponsor: V Fdtn for Cancer Research
    PI:Luca, V.
  • Deciphering MDSC function for GBM targeting
    Sponsor: Nat Institutes of Health
    PI (MPI):Vogelbaum, M.
  • North American Star Consortium
    Sponsor: Nat Institutes of Health
    PI (MPI):Lancet, J.
  • MPN Research Consortium
    Sponsor: Nat Institutes of Health
    PI:Komrokji, R.
  • SWOG Network Group Operators Center of the NCTN
    Sponsor: Nat Institutes of Health
    PI:Khushalani, N.
  • Developing Video Content to Foster Leadership Education through Coaching and Emotional Intelligence
    Sponsor: American Medical Association (AMA)
    PI:Frakes, J.
  • New Therapeutic Vulnerabilities for Pediatric Burkitt Lymphoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Tao, J.
  • Characterizing oncogenic function of ITCH in melanoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Wan, L.
  • Novel Monovalent and Bivalent JAK2 Inhibitors for Targeted MPN and Cancer Therapies
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Lawrence, N.,CO-PI:Schonbrunn, E.
  • Development of Novel Cancer Drugs for the Treatment of Multiple Myeloma and Acute Myeloid Leukemia
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Shain, K.,CO-PI:Meads, M.
  • Proteogenomics of Metastatic Heterogeneity and Therapeutic Resistance inLung Cancer
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI (Contact):Koomen, J.,CO-PI:Boyle, T.
  • NRG Oncology Network Group Operations Center
    Sponsor: Nat Institutes of Health
    PI:Vogelbaum, M.
  • Lung Cancer Diagnostic Testing Program
    Sponsor: The Salah Foundation
    PI:Haura, E.
  • Adrenergic Signaling Inhibition to Enhance the Immunogenecity of the Ovarian Tumor Microenvironment Prior to PD-1 Checkpoint Therapy
    Sponsor: Nat Institutes of Health
    PI:Chen, D.
  • Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer
    Sponsor: Nat Institutes of Health
    PI (MPI):Gray, J.
  • Phase 1-Open-Label-Dose-Escal w Expansion Study-SX-682 in Subjects w Myelodysplastic Syndrome w Disease Progression or Intolerant to Prior Therapy
    Sponsor: Nat Institutes of Health
    PI:Sallman, D.
  • Modulating Glioblastoma Stem Cell Clonal Evolution Towards Therapeutic Responsiveness
    Sponsor: Nat Institutes of Health
    PI:Etame, A.
  • T-Cell, Monocyte, and Cytokine Profiling to Identify Correlates of KTE-C19 Persistence, Toxicity, and Long Term Remission in B-cell Acute Lymphoblastic Leukemia - ISR-2018-10055
    Sponsor: Kite Pharma
    PI:Shah, B.
  • Use of Tumor Samples from Rapid Tissue Donation to Explore Inflammation, Mechanisms of I-O Resistance, and Tumor Neoantigen Landscape
    Sponsor: Bristol Myers Squibb Company
    PI:Boyle, T.,CO-PI:Beg, A.
  • Elucidating Cdc20-mediated transcriptional reprogramming in ovarian cancer
    Sponsor: Moffitt Cancer Center
    PI:Wan, L.
  • Phenotyping the Microenvironment in GI Cancers
    Sponsor: Oncologie, Inc.
    PI:Malafa, M.
  • S2000: A Randomized Phase 2 trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAFV600-Mutant Melanoma Brain Metastases
    Sponsor: The Hope Fdtn
    PI (Contact):Eroglu, Z.
  • CTEP-Leidos Payment Agreement
    Sponsor: Leidos Biomedical Research, Inc.
    PI:Baz, R.
  • SWOG NCORP Research Base
    Sponsor: Nat Institutes of Health
    PI:Khushalani, N.
  • Aprea Central Lab Study
    Sponsor: Aprea Therapeutics AB
    PI:Sallman, D.
  • Promoting healthy adipocyte function: a novel therapeutic strategy to uncouple obesity from metabolic disease and co-morbidities
    Sponsor: Moffitt Cancer Center
    PI:McDonald, P.
  • The Genomics of MPNST (GeM) Consortium
    Sponsor: NF Research Initiative
    PI:Bui, M.
  • Defining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy Escape
    Sponsor: Nat Institutes of Health
    PI:Smalley, I.
  • Ex Vivo Studies of AbbVie’s Proprietary Compounds in Multiple Myeloma #2
    Sponsor: AbbVie, Inc.
    PI:Shain, K.,CO-PI:Silva, A.
  • Effects of hypoxia in tumor immune microenvironment in tobacco-related head and neck squamous cell carcinoma (HNSCC)
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Chung, C.,CO-PI:Tan, A.
  • Characterization of PARP16 as a novel target in Ewing’s sarcoma
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Rix, U.
  • Enhancement of Immune Checkpoint inhibition with Lurbinectedin modulation in relapsed/recurrent small cell lung cancer (SCLC)
    Sponsor: Bristol Myers Squibb Company
    PI:Chiappori, A.
  • Investigating the Role of a Novel Dendritic Cell Population as a Central Regulator of a Favorable Immune Environment in Melanoma
    Sponsor: Melanoma Research Foundation
    PI:Smalley, K.
  • Evaluation of MHC class I methylation as a mechanism of checkpoint inhibitor resistance in head and neck squamous cell carcinoma (HNSCC)
    Sponsor: Bristol Myers Squibb Company
    PI:Chung, C.
  • Targeting USP9X-mediated RIT1 stabilization for cancer therapy
    Sponsor: Amer Cancer Society
    PI:Wan, L.
  • Correlative study on OS2966 binding activity in glioma
    Sponsor: Oncosynergy, Inc.
    PI:Liu, J.
  • Exploring Correlation Between RTK Activation Status and KRAS G12C(ON) Inhibitor Sensitivity, and Developing New PLA Assays to Inform RAS and mTOR Pathways
    Sponsor: Revolution Medicines Inc
    PI:Haura, E.
  • Exploring Correlation Between EGFR/MET Activation Status and RMC-4630 Sensitivity in Tumor Tissue Using PLA Assays
    Sponsor: Revolution Medicines Inc
    PI:Haura, E.
  • Response to Aspirin Prevention of Colorectal Cancer Mortality in African Americans
    Sponsor: Moffitt Cancer Center
    PI:Malafa, M.,CO-PI:Schell, M.
  • Defining KRAS-G12C Inhibitor Antitumor Synergy with Adoptive T Cell Therapy Through Potentiation of Cytokine Signaling and Sensitization to Cell Death
    Sponsor: Moffitt Cancer Center
    PI:Haura, E.
  • Analysis of Clinical and Economic Outcomes in Patients with Myelodysplastic Syndrome in Academic Centers, a Multisite Cohort Study
    Sponsor: Novartis Pharmaceuticals Corp.
    PI:Talati, C.
Publications
  • Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021 Dec.26(1):393-397. Pubmedid: 34029507.
  • Robinson LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, Bui MM, Druta M. Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas. J Thorac Cardiovasc Surg. 2021 Jul.162(1):274-284. Pubmedid: 32711968.
  • Mulroney CM, Bilal Abid M, Bashey A, Chemaly RF, Ciurea SO, Chen M, Dandoy CE, Diaz Perez MA, Friend BD, Fuchs E, Ganguly S, Goldsmith SR, Kanakry CG, Kim S, Komanduri KV, Krem MM, Lazarus HM, Ljungman P, Maziarz R, Nishihori T, Patel SS, Perales MA, Romee R, Singh AK, Reid Wingard J, Yared J, Riches M, Taplitz R. Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. Brit J Haematol. 2021 Jul.194(1):145-157. Pubmedid: 34124796.
  • Britt J, Jain R, Li R. Robotic radical nephroureterectomy in a patient with situs inversus totalis. Urol Case Rep. 2021 Jul.37:101688. Pubmedid: 34040986. Pmcid: PMC8141754.
  • Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021 Jul.127(13):2251-2261. Pubmedid: 33826754.
  • Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.
  • Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
  • Parikh N, Keshishian E, Manley B, Grass GD, Torres-Roca J, Boulware D, Feuerlein S, Pow-Sang JM, Bagla S, Yamoah K, Bhatia S. Effectiveness and Safety of Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia in Men with Concurrent Localized Prostate Cancer. J Vasc Interv Radiol. 2021 Jul.32(7):1053-1061. Pubmedid: 33794373.
  • Kim J, She C, Potez M, Huang P, Wu Q, Prager BC, Qiu Z, Bao S, Rich JN, Liu JKC. Phage display targeting identifies EYA1 as a regulator of glioblastoma stem cell maintenance and proliferation. Stem Cells. 2021 Jul.39(7):853-865. Pubmedid: 33594762.
  • Wang X, Ma J, Bhosale P, Ibarra Rovira JJ, Qayyum A, Sun J, Bayram E, Szklaruk J. Novel deep learning-based noise reduction technique for prostate magnetic resonance imaging. Abdom Radiol (NY). 2021 Jul.46(7):3378-3386. Pubmedid: 33580348. Pmcid: PMC8215028.
  • Wang Z, Li Z, Ji H. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives. Med Res Rev. 2021 Jul.41(4):2109-2129. Pubmedid: 33475177. Pmcid: PMC8217106.
  • Faries MB, Ascierto PA, Blank C, Cochran AJ, Delman K, Gyorki D, Haanen J, Hamid O, Han D, Karakousis G, Kashani-Sabet M, Leachman S, Moncrieff M, Plasmeijer E, Enrico Testori AA, Van Akkooi A, Wong S, Zager JS. Letter Regarding Editorial by Samuel Zagarella. Am J Dermatopathxxx. 2021 Jul.43(7):539-541. Pubmedid: 33264129.
  • Straker RJ, Song Y, Sun J, Shannon AB, Cohen LS, Muradova E, Daou H, Krause K, Li S, Frederick DT, Rhodin KE, Brizel DM, Boland GM, Beasley GM, Wuthrick EJ, Sondak VK, Zager JS, Lin A, Lukens JN, Karakousis GC. Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul.28(7):3512-3521. Pubmedid: 33230747.
  • Pollyea DA, Kim HM, Stevens BM, Lee FF, Harris C, Hedin BR, Knapp JR, O'Connor BP, Jordan CT, Pietras EM, Tan AC, Alper S. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. J Leukoc Biol. 2021 Jul.110(1):197-205. Pubmedid: 33155727.
  • Niell BL, Abdalah M, Stringfield O, Raghunand N, Ataya D, Gillies R, Balagurunathan Y. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk. Ajr Am J Roentgenol. 2021 Jul.217(1):64-75. Pubmedid: 32876474.
  • Kelly RJ, Ansari AM, Miyashita T, Zahurak M, Lay F, Ahmed AK, Born LJ, Pezhouh MK, Salimian KJ, Ng C, Matsangos AE, Stricker-Krongrad AH, Mukaisho KI, Marti GP, Chung CH, Canto MI, Rudek MA, Meltzer SJ, Harmon JW. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma. Ann Surg. 2021 Jun.273(6):e206-e213. Pubmedid: 31290765. Pmcid: PMC8147663.
  • Gao J, Wang MY, Ren Y, Lwin T, Li T, Yan JC, Sotomayor EM, Duckett DR, Shah BD, Shain KH, Zhao X, Tao J. Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. Haematologica. 2021 Jun. Pubmedid: 34162179.
  • Roper N, Velez MJ, Chiappori A, Kim YS, Wei JS, Sindiri S, Takahashi N, Mulford D, Kumar S, Ylaya K, Trindade C, Manukyan I, Brown AL, Trepel JB, Lee JM, Hewitt S, Khan J, Thomas A. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nat Commun. 2021 Jun.12(1):3880. Pubmedid: 34162872.
  • Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Jun. Pubmedid: 34161051.
  • Mu W, Jiang L, Shi Y, Tunali I, Gray JE, Katsoulakis E, Tian J, Gillies RJ, Schabath MB. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34135101. Pmcid: PMC8211060.
  • Jinesh GG, Napoli M, Smallin MT, Davis A, Ackerman HD, Raulji P, Montey N, Flores ER, Brohl AS. Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma. Sci Rep. 2021 Jun.11(1):12673. Pubmedid: 34135394. Pmcid: PMC8209049.
  • Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 Jun. Pubmedid: 34138638.
  • Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. PLoS One. 2021 Jun.16(6):e0252927. Pubmedid: 34138895. Pmcid: PMC8211232.
  • Castillo Tokumori F, Komrokji R, Kuykendall AT. Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera. Expert Opin Emerg Drugs. 2021 Jun.1-10. Pubmedid: 34139920.
  • Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 Jun. Pubmedid: 34143979.
  • Hunter AM, Al Ali N, Mai A, Shah S, Swoboda DM, Kuykendall A, Talati C, Sweet KL, Sallman DA, Lancet JE, Komrokji RS, Padron E. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leuk Res. 2021 Jun.109:106640. Pubmedid: 34144312.
  • Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, Lazarus HM, Paietta EM, Tallman MS, Litzow MR. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Brit J Haematol. 2021 Jun. Pubmedid: 34145576.
  • Felder SI, Fleming JB, Gatenby RA. Treatment-induced evolutionary dynamics in nonmetastatic locally advanced rectal adenocarcinoma. Adv Cancer Res. 2021 Jun.151:39-67. Pubmedid: 34148619.
  • Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, Zager JS, Sondak VK, Messina JL, Pockaj B, Kosiorek HE, Vetto J, Fowler G, Schneebaum S, Han D. Regression is significantly associated with outcomes for patients with melanoma. Surgery. 2021 Jun. Pubmedid: 34120749.
  • Goduni L, Ashkenazy N, Hansen E, Soyano-Muller A, Correa ZM, Harbour JW. Iris metastasis from breast cancer successfully treated with Abemaciclib and Letrozole. Retin Cases Brief Rep. 2021 Jun. Pubmedid: 34127625.
  • Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, Wang Q, Zhu C, Dai B, Kang Y, Han L, Feng N, Jin Y, Fleming J, Heffernan TP, Yao W, Ying H. Targeting glucose metabolism sensitizes pancreatic cancer to MEK inhibition. Cancer Res. 2021 Jun. Pubmedid: 34117030.
  • Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Sallman D. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leuk Lymphoma. 2021 Jun.1-6. Pubmedid: 34114922.
  • Carr MJ, Monzon FA, Zager JS. Sentinel lymph node biopsy in melanoma: beyond histologic factors. Clin Exp Metastas. 2021 Jun. Pubmedid: 34100196.
  • Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jun. Pubmedid: 34091601.
  • Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34083421. Pmcid: PMC8183204.
  • Khushalani NI, Truong TG, Thompson JF. Current Challenges in Access to Melanoma Care: A Multidisciplinary Perspective. Am Soc Clin Oncol Educ Book. 2021 Jun.41:e295-e303. Pubmedid: 34061557.
  • Jain AG, Talati C, Pinilla-Ibarz J. Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia. Expert Opin Inv Drug. 2021 Jun.30(6):595-601. Pubmedid: 34053383.
  • Grass GD, Scott JG, Sedor G, Kattan MW, Torres-Roca JF. Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose. J Thorac Oncol. 2021 Jun.16(6):e48-e49. Pubmedid: 34034894.
  • Koomen DC, Meads MB, Magaletti DM, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA, Meke LE, Jiang Z, Hampton OA, Tungesvik A, De Avila G, Alugubelli RR, Nishihori T, Silva AS, Eschrich SA, Garrett TJ, Koomen JM, Shain KH. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. J Proteome Res. 2021 Jun.20(6):3134-3149. Pubmedid: 34014671.
  • van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2021 Jun.22(6):813-823. Pubmedid: 34000245. Pmcid: PMC8191233.
  • Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun.22(6):848-857. Pubmedid: 34000246.
  • de Mingo Pulido Á, Hänggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, Mohamed E, Trillo-Tinoco J, Osunmakinde O, Peña R, Onimus A, Kaisho T, Kaufmann J, McEachern K, Soliman H, Luca VC, Rodriguez PC, Yu X, Ruffell B. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021 Jun.54(6):1154-1167.e7. Pubmedid: 33979578. Pmcid: PMC8192496.
  • Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, Zhang Z, Xu K, Duan J, He S, Zhang J, Wan L, Liu T, Zhou X, Hung MC, Freeman GJ, Wei W. Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Mol Cell. 2021 Jun.81(11):2317-2331.e6. Pubmedid: 33909988. Pmcid: PMC8178223.
  • Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, Volgman AS, Moseley KF, Porter CB, Ismail-Khan R. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2021 Jun.14(3):e000082. Pubmedid: 33896190.
  • Belzarena AC, Binitie O, Letson D, Joyce DM. Intramedullary rod failure in metastatic breast cancer: Do triple negative cancer patients have more revision surgery?. J Bone Oncol. 2021 Jun.28:100358. Pubmedid: 33898214. Pmcid: PMC8056433.
  • Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021 Jun.13(9):727-734. Pubmedid: 33878954.
  • Strosberg J, Leeuwenkamp O, Siddiqui MK. Corrigendum to "Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis" [Cancer Treatm. Rev. 93 (2021) 102141]. Cancer Treat Rev. 2021 Jun.97:102203. Pubmedid: 33857824.
  • Schubert L, Le AT, Estrada-Bernal A, Doak AE, Yoo M, Ferrara SE, Goodspeed A, Kinose F, Rix U, Tan AC, Doebele RC. Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. Mol Pharmacol. 2021 Jun.99(6):435-447. Pubmedid: 33795352.
  • Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, Extermann M, Chon HS. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. Gynecol Oncol. 2021 Jun.161(3):693-699. Pubmedid: 33812698.
  • Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Jun.35(6):1828. Pubmedid: 33782538. Pmcid: PMC8188513.
  • Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021 Jun.27(6):483.e1-483.e6. Pubmedid: 33775615. Pmcid: PMC8217373.
  • Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021 Jun.32(6):746-756. Pubmedid: 33741442.
  • Tesileanu CMS, Vallentgoed WR, Sanson M, Taal W, Clement PM, Wick W, Brandes AA, Baurain JF, Chinot OL, Wheeler H, Gill S, Griffin M, Rogers L, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, de Vos F, Mulholland PJ, Taphoorn MJB, de Heer I, Hoogstrate Y, de Wit M, Boggiani L, Venneker S, Oosting J, Bovée JVMG, Erridge S, Vogelbaum MA, Nowak AK, Mason WP, Kros JM, Wesseling P, Aldape K, Jenkins RB, Dubbink HJ, Baumert B, Golfinopoulos V, Gorlia T, van den Bent M, French PJ. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol. 2021 Jun.141(6):945-957. Pubmedid: 33740099. Pmcid: PMC8113211.
  • Chan O, Renneville A, Padron E. Chronic myelomonocytic leukemia diagnosis and management. Leukemia. 2021 Jun.35(6):1552-1562. Pubmedid: 33714974.
  • Jha A, Taieb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru A, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K. High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2021 Jun.27(11):2989-2995. Pubmedid: 33685867. Pmcid: PMC8172462.
  • Sevin M, Debeurme F, Laplane L, Badel S, Morabito M, Newman HL, Torres-Martin M, Yang Q, Badaoui B, Wagner-Ballon O, Saada V, Selimoglu-Buet D, Kraus-Berthier L, Banquet S, Derreal A, Fenaux P, Itzykson RA, Braun T, Etienne G, Berthon C, Thepot S, Kepp O, Kroemer G, Padron E, Figueroa ME, Droin NM, Solary E. Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. Blood. 2021 Jun.137(24):3390-3402. Pubmedid: 33690800.
  • Hunter A, Padron E. Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep. 2021 Jun.16(3):247-255. Pubmedid: 33660195.
  • Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, Chemaly RF, Chen M, Ciurea SO, Dandoy CE, Angel Diaz M, Fuchs EJ, Ganguly S, Kanakry CG, Kanakry JA, Kim S, Komanduri K, Krem M, Lazarus HM, Liu H, Ljungman P, Maziarz RT, Mulroney C, Nathan S, Nishihori T, Page KM, Perales MA, Taplitz RA, Romee R, Riches M. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 Jun.137(23):3291-3305. Pubmedid: 33657221.
  • Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 Jun.21(6):421-424.e2. Pubmedid: 33583730.
  • Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol. 2021 Jun.43(3):426-432. Pubmedid: 33220019. Pmcid: PMC8247031.
  • Broman KK, Joyce D, Binitie O, Letson GD, Gonzalez RJ, Choi J, Mullinax JE. Intraoperative Localization Using an Implanted Radar Reflector Facilitates Resection of Non-Palpable Trunk and Extremity Sarcoma. Ann Surg Oncol. 2021 Jun.28(6):3366-3374. Pubmedid: 33073344.
  • Gesiotto Q, Zhang Y, Malik A, Seminario-Vidal L, Ayala E, Zhang L, Sokol L. Long-Term Remission After Matched Sibling Donor Hematopoietic Cell Transplantation in a Patient With Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. Cureus. 2021 May.13(5):e15132. Pubmedid: 34159034. Pmcid: PMC8214246.
  • Alok A, Greene J. Necrotizing Cellulitis and Myositis in a Neutropenic Leukemic Patient. Cureus. 2021 May.13(5):e14941. Pubmedid: 34123638. Pmcid: PMC8189531.
  • Sandoval-Sus J, Chavez JC. The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. Ther Adv Hematol. 2021 May.12. Pubmedid: 34104371. Pmcid: PMC8165824.
  • Boyle TA, Mondal AK, Saeed-Vafa D, Ananth S, Ahluwalia P, Kothapalli R, Chaubey A, Roberts E, Qin D, Magliocco AM, Rojiani AM, Kolhe R. Guideline-Adherent Clinical Validation of a Comprehensive 170-Gene DNA/RNA Panel for Determination of Small Variants, Copy Number Variations, Splice Variants, and Fusions on a Next-Generation Sequencing Platform in the CLIA Setting. Front Genet. 2021 May.12:503830. Pubmedid: 34093633. Pmcid: PMC8172991.
  • Hicks JK, Howard R, Reisman P, Adashek JJ, Fields KK, Gray JE, McIver B, McKee K, O'Leary MF, Perkins RM, Robinson E, Tandon A, Teer JK, Markowitz J, Rollison DE. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precis Oncol. 2021 May.5. Pubmedid: 34095711. Pmcid: PMC8169076.
  • Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Mesa R, Yacoub A, Hoffman R, Moshier E, Zubizarreta N, Mascarenhas J. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res. 2021 May.109:106629. Pubmedid: 34082375.
  • Fradley MG, Alomar M, Kilpatrick MW, Shields B, Tran N, Best A, Bianco E, Armanious M, Vautier RA, Kip K, Beckie TM, Ismail-Khan R. Patient reported physical and mental health changes associated with a comprehensive cardiovascular risk reduction program for women with breast cancer receiving potentially cardiotoxic chemotherapy. Cardiooncology. 2021 May.7(1):22. Pubmedid: 34059163. Pmcid: PMC8166098.
  • Watson G, Lester D, Ren H, Forsyth CM, Medina E, Gonzalez Perez D, Darville L, Yao J, Luca V, Koomen J, Cen L, Lau E. Fucosylated Proteome Profiling Identifies a Fucosylated, Non-Ribosomal, Stress-Responsive Species of Ribosomal Protein S3. Cells. 2021 May.10(6). Pubmedid: 34070332. Pmcid: PMC8228307.
  • Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Saunthararajah Y, Shain KH, Maciejewski JP, Reu FJ, Phillips JG, Jha BK. Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. Cancers (Basel). 2021 May.13(11). Pubmedid: 34071205. Pmcid: PMC8198550.
  • Cortes A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplant Cell Ther. 2021 May. Pubmedid: 34077811.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 May. Pubmedid: 34035069.
  • Komrokji RS, Volpe VO, Chan O, Al Ali NH, Swoboda DM, Kuykendall AT, Padron E, Sallman DA. Validation of the International Working Group Proposal for SF3B1 Mutant Myelodysplastic Syndromes. Blood. 2021 May. Pubmedid: 34036300.
  • Nieto A, Bailey T, Kaczanowska K, McDonald P. GABAB Receptor Chemistry and Pharmacology: Agonists, Antagonists, and Allosteric Modulators. Curr Top Behav Neurosci. 2021 May. Pubmedid: 34036555.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 May. Pubmedid: 34032503.
  • Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open. 2021 May.4(5):e2111329. Pubmedid: 34032854. Pmcid: PMC8150693.
  • Kohale IN, Burgenske DM, Mladek AC, Bakken KK, Kuang J, Boughey JC, Wang L, Carter JM, Haura EB, Goetz MP, Sarkaria JN, White FM. Quantitative analysis of tyrosine phosphorylation from FFPE tissues reveals patient-specific signaling networks. Cancer Res. 2021 May. Pubmedid: 34016623.
  • Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 May. Pubmedid: 34017072.
  • Carr RM, Vorobyev D, Lasho T, Marks DL, Tolosa EJ, Vedder A, Almada LL, Yurcheko A, Padioleau I, Alver B, Coltro G, Binder M, Safgren SL, Horn I, You X, Solary E, Balasis ME, Berger K, Hiebert J, Witzig T, Buradkar A, Graf T, Valent P, Mangaonkar AA, Robertson KD, Howard MT, Kaufmann SH, Pin C, Fernandez-Zapico ME, Geissler K, Droin N, Padron E, Zhang J, Nikolaev S, Patnaik MM. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021 May.12(1):2901. Pubmedid: 34006870. Pmcid: PMC8131698.
  • Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
  • Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2021 May. Pubmedid: 33992782.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2021 May. Pubmedid: 33994165.
  • Patel A, Carr MJ, Sun J, Zager JS. In-transit metastatic cutaneous melanoma: current management and future directions. Clin Exp Metastas. 2021 May. Pubmedid: 33999365.
  • Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ Precis Oncol. 2021 May.5(1):41. Pubmedid: 34001994. Pmcid: PMC8129124.
  • Eschrich SA, Teer JK, Reisman P, Siegel E, Challa C, Lewis P, Fellows K, Malpica E, Carvajal R, Gonzalez G, Cukras S, Betin-Montes M, Aden-Buie G, Avedon M, Manning D, Tan AC, Fridley BL, Gerke T, Van Looveren M, Blake A, Greenman J, Rollison D. Enabling Precision Medicine in Cancer Care Through a Molecular Data Warehouse: The Moffitt Experience. JCO Clin Cancer Inform. 2021 May.5:561-569. Pubmedid: 33989014.
  • Mansouri A, Beyn ME, Pancholi A, Chow CT, Wang R, Boutet A, Elias GJB, Germann J, Loh A, Voisin MR, Lozano AM, Chiocca EA, Vogelbaum MA, Zadeh G. Evolution of the Neurosurgeon's Role in Clinical Trials for Glioblastoma: A Systematic Overview of the Clinicaltrials.Gov Database. Neurosurgery. 2021 May. Pubmedid: 33989408.
  • Smalley KSM, Teer JK, Chen YA, Wu JY, Yao J, Koomen JM, Chen WS, Rodriguez-Waitkus P, Karreth FA, Messina JL. A Mutational Survey of Acral Nevi. JAMA Dermatol. 2021 May. Pubmedid: 33978681. Pmcid: PMC8117064.
  • Monastyrskyi A, Brockmeyer F, LaCrue AN, Zhao Y, Maher SP, Maignan JR, Padin-Irizarry V, Sakhno YI, Parvatkar PT, Asakawa AH, Huang L, Casandra D, Mashkouri S, Kyle DE, Manetsch R. Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1H)-Quinolones with Single Dose Cures. J Med Chem. 2021 May.64(10):6581-6595. Pubmedid: 33979164.
  • Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021 May.JCO2100612. Pubmedid: 33979178.
  • Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA. Cellular Therapies for Mantle Cell Lymphoma. Transplant Cell Ther. 2021 May.27(5):363-370. Pubmedid: 33965173.
  • Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 May.9(5). Pubmedid: 33963015. Pmcid: PMC8108687.
  • Berglund A, Putney RM, Hamaidi I, Kim S. Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. Exp Mol Med. 2021 May.53(5):761-771. Pubmedid: 33963293. Pmcid: PMC8178403.
  • Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 May.JCO2100079. Pubmedid: 33945288.
  • Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W, Kumthekar P. Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. J Clin Oncol. 2021 May.JCO2002822. Pubmedid: 33945296.
  • Jalali S, Jenneman D, Tandon A, Khong H. Thrombotic Microangiopathy: A Rare Breast Cancer-associated Complication Treated Successfully With Doxorubicin and Cyclophosphamide. In Vivo. 2021 May.35(3):1885-1888. Pubmedid: 33910877. Pmcid: PMC8193307.
  • Wang Z, Zhang M, Luo W, Zhang Y, Ji H. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. J Med Chem. 2021 May.64(9):5886-5904. Pubmedid: 33902288.
  • Sedor G, Scott JG, Kattan MW, Torres-Roca JF. Letter Response. J Thorac Oncol. 2021 May.16(5):e28-e29. Pubmedid: 33896574.
  • Buras AL, Mallen A, Wenham R, Montejo M. Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy. Gynecol Oncol Rep. 2021 May.36:100754. Pubmedid: 33869712. Pmcid: PMC8042429.
  • Muthengi A, Wimalasena VK, Yosief HO, Bikowitz MJ, Sigua LH, Wang T, Li D, Gaieb Z, Dhawan G, Liu S, Erickson J, Amaro RE, Schönbrunn E, Qi J, Zhang W. Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors. J Med Chem. 2021 May.64(9):5787-5801. Pubmedid: 33872011.
  • Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Brit J Cancer. 2021 May.124(11):1803-1808. Pubmedid: 33828254. Pmcid: PMC8144213.
  • Karschnia P, Vogelbaum MA, van den Bent M, Cahill DP, Bello L, Narita Y, Berger MS, Weller M, Tonn JC. Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021 May.149:23-33. Pubmedid: 33819718.
  • Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 May.27(5):410-422. Pubmedid: 33775617. Pmcid: PMC8168834.
  • Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: 33753457. Pmcid: PMC8127396.
  • Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
  • Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May.39(15):1609-1618. Pubmedid: 33683917. Pmcid: PMC8148421.
  • Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett D, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunol Res. 2021 May.9(5):554-567. Pubmedid: 33653716. Pmcid: PMC8102376.
  • Solanki HS, Welsh EA, Fang B, Izumi V, Darville LNF, Stone B, Franzese R, Chavan S, Kinose F, Imbody D, Koomen JM, Rix U, Haura EB. Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition. Clin Cancer Res. 2021 May.27(9):2533-2548. Pubmedid: 33619172.
  • Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021 May.39(14):1575-1583. Pubmedid: 33600210. Pmcid: PMC8099409.
  • Vogelbaum MA, Kroll D, Etame A, Tran N, Liu J, Ford A, Sparr E, Kim Y, Forsyth P, Sahebjam S, Mokhtari S, Peguero E, Macaulay R. A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA-Induced Fluorescence in High-Grade Gliomas. World Neurosurg. 2021 May.149:e498-e503. Pubmedid: 33561551.
  • Shallis RM, Bewersdorf JP, Swoboda DM, Wei W, Gowda L, Prebet T, Halene S, Pillai MM, Parker T, Neparidze N, Podoltsev NA, Seropian S, Sallman DA, Gore SD, Zeidan AM. Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 May.21(5):e483-e487. Pubmedid: 33551344.
  • Lo CH, Shay G, McGuire J, Li T, Shain K, Choi JY, Fuerst R, Roush WR, Knapinska AM, Fields GB, Lynch CC. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival. Cancer Res. 2021 May.81(9):2415-2428. Pubmedid: 33526510.
  • Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
  • Faivre-Finn C, Vicente D, Kurata T, Planchard D, Paz-Ares L, Vansteenkiste JF, Spigel DR, Garassino MC, Reck M, Senan S, Naidoo J, Rimner A, Wu YL, Gray JE, Özgüroğlu M, Lee KH, Cho BC, Kato T, de Wit M, Newton M, Wang L, Thiyagarajah P, Antonia SJ. Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol. 2021 May.16(5):860-867. Pubmedid: 33476803.
  • Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 May.39(14):1584-1594. Pubmedid: 33449813. Pmcid: PMC8099410.
  • Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gerhsenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 May.27(10):2678-2697. Pubmedid: 33414132. Pmcid: PMC8127340.
  • Zeidan AM, Komrokji RS, Brunner AM. TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther. 2021 May.21(5):523-534. Pubmedid: 33334180.
  • Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, Kim DDH, Hernandez D, Rajkhowa T, Haines K, Bonifacio G, Rine P, Purkayastha D, Fernandez HF. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021 May.56(5):1180-1189. Pubmedid: 33288862. Pmcid: PMC8113057.
  • Baldassarre LA, Yang EH, Cheng RK, DeCara JM, Dent S, Liu JE, Rudski LG, Strom JB, Thavendiranathan P, Barac A, Zaha VG, Bucciarelli-Ducci C, Ellahham S, Deswal A, Lenneman C, Villarraga HR, Blaes AH, Ismail-Khan R, Ky B, Leja MJ, Scherrer-Crosbie M. Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. J Natl Cancer Inst. 2021 May.113(5):513-522. Pubmedid: 33179744. Pmcid: PMC7717327.
  • Felder SI, Feuerlein S, Parsee A, Imanirad I, Sanchez J, Dessureault S, Kim R, Hoffe S, Frakes J, Costello J. Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples. Abdom Radiol (NY). 2021 May.46(5):1783-1804. Pubmedid: 33111189.
  • Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 May.9(5):467-475. Pubmedid: 33096027.
  • Mallen AR, Conley CC, Fuzzell L, Ketcher D, Augusto BM, McIntyre M, Barton LV, Townsend MK, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST. "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer. Support Care Cancer. 2021 May.29(5):2663-2677. Pubmedid: 32975643. Pmcid: PMC7981241.
  • Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
  • Jain RK, Skelton Iv WP, Pond GR, Naqvi M, Kim Y, Curran C, Freeman D, Nuzzo PV, Alaiwi SA, Nassar AH, Jain RK, Sonpavde G. Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2021 Apr. Pubmedid: 34011489.
  • Pimiento JM, Evans DC, Tyler R, Barrocas A, Hernandez B, Araujo-Torres K, Guenter P. Value of nutrition support therapy in patients with gastrointestinal malignancies: a narrative review and health economic analysis of impact on clinical outcomes in the United States. J Gastrointest Oncol. 2021 Apr.12(2):864-873. Pubmedid: 34012673. Pmcid: PMC8107619.
  • Wilkes JG, Patel A, Zager JS. Local and regional therapy for primary and locally recurrent melanoma. Clin Adv Hematol Oncol. 2021 Apr.19(4):246-260. Pubmedid: 33989273.
  • Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas. 2021 Apr.50(4):506-512. Pubmedid: 33939661. Pmcid: PMC8097723.
  • Al-Toubah T, Sikaria D, Jesurajan J, Bottiglieri S, Smith J, Pellé E, Hutchinson T, Strosberg J, El-Haddad G. Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy: Commercial Parenteral Nutrition Formulas Versus Compounded Arginine/Lysine. Pancreas. 2021 Apr.50(4):513-515. Pubmedid: 33939662.
  • Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK, Padron E, Talati C, Patnaik MM. Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia. 2021 Apr. Pubmedid: 33931725.
  • Lin HY, Huang PY, Cheng CH, Tung HY, Fang Z, Berglund AE, Chen A, French-Kwawu J, Harris D, Pow-Sang J, Yamoah K, Cleveland JL, Awasthi S, Rounbehler RJ, Gerke T, Dhillon J, Eeles R, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Neal DE, Nielsen SF, Nordestgaard BG, Gronberg H, Wiklund F, Giles GG, Haiman CA, Travis RC, Stanford JL, Kibel AS, Cybulski C, Khaw KT, Maier C, Thibodeau SN, Teixeira MR, Cannon-Albright L, Brenner H, Kaneva R, Pandha H, Srinivasan S, Clements J, Batra J, Park JY. KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci Rep. 2021 Apr.11(1):9264. Pubmedid: 33927218. Pmcid: PMC8084951.
  • Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021 Apr.JCO2003489. Pubmedid: 33929895.
  • Tesileanu CMS, van den Bent MJ, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Sabedot TS, Hoogstrate Y, von Deimling A, de Heer I, van IJcken WFJ, Brouwer RWW, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, Noushmehr H, French PJ. Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neurooncol. 2021 Apr. Pubmedid: 33914057.
  • Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplant Cell Ther. 2021 Apr. Pubmedid: 33895402.
  • Al-Toubah T, Strosberg J. Progress in TNM staging of pancreatic neuroendocrine tumors. Hepatobiliary Surg Nutr. 2021 Apr.10(2):238-240. Pubmedid: 33898566. Pmcid: PMC8050571.
  • Ahmad SB, Rice M, Chang C, Hamad A, Kingham TP, He J, Pimiento JM, Zureikat AH, Zeh HJ, Hogg ME. ASO Visual Abstract: Will It Play in Peoria? A Pilot Study of a Robotic Skills Curriculum for Surgical Oncology Fellows. Ann Surg Oncol. 2021 Apr. Pubmedid: 33900498.
  • Xie M, Lee K, Lockhart JH, Cukras SD, Carvajal R, Beg AA, Flores ER, Teng M, Chung CH, Tan AC. TIMEx: tumor-immune microenvironment deconvolution web-portal for bulk transcriptomics using pan-cancer scRNA-seq signatures. Bioinformatics. 2021 Apr. Pubmedid: 33901274.
  • Lee AY, Friedman EB, Sun J, Potdar A, Daou H, Farrow NE, Farley CR, Vetto JT, Han D, Tariq M, Shapiro R, Beasley G, Contreras CM, Osman I, Lowe M, Zager JS, Berman RS. Correction to: The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. Ann Surg Oncol. 2021 Apr. Pubmedid: 33893602.
  • Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget. 2021 Apr.12(8):756-766. Pubmedid: 33889299. Pmcid: PMC8057275.
  • Straker RJ, Carr MJ, Sinnamon AJ, Shannon AB, Sun J, Landa K, Baecher KM, Wood C, Lynch K, Bartels HG, Panchaud R, Lowe MC, Slingluff CL, Jameson MJ, Tsai K, Faries MB, Beasley GM, Sondak V, Karakousis GC, Zager JS, Miura JT. Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Ann Surg Oncol. 2021 Apr. Pubmedid: 33890195.
  • Ward GA, McGraw KL, Abbas-Aghababazadeh F, Meyer BS, McLemore AF, Vincelette ND, Lam NB, Aldrich AL, Al Ali NH, Padron E, Pinilla-Ibarz J, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Johnson J, Fridley BL, List AF. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Adv. 2021 Apr.5(8):2216-2228. Pubmedid: 33890980. Pmcid: PMC8095151.
  • Denbo JW, Kim R, Anaya DA. ASO Author Reflections: Evolving Treatment Paradigms for High-Risk Intrahepatic Cholangiocarcinoma: What Does The Future Hold?. Ann Surg Oncol. 2021 Apr. Pubmedid: 33891197.
  • Kazi A, Chen L, Xiang S, Vangipurapu R, Yang H, Beato F, Fang B, Williams TM, Husain K, Underwood PW, Fleming JB, Malafa MP, Welsh EA, Koomen JM, Trevino JG, Sebti SM. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Clin Cancer Res. 2021 Apr. Pubmedid: 33879459.
  • Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021 Apr.9(4). Pubmedid: 33879601. Pmcid: PMC8061836.
  • Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA. Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204). Neurooncol. 2021 Apr. Pubmedid: 33880555.
  • Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-Grade Neuroendocrine Neoplasm Cohort. Cancer. 2021 Apr. Pubmedid: 33882143.
  • Pimiento JM, Dineen SP. ASO Author Reflections: Gastric Cancer with Peritoneal Metastasis: Are Some Patients Surgical Candidates?. Ann Surg Oncol. 2021 Apr. Pubmedid: 33866470.
  • Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK, Fishman MN. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol. 2021 Apr. Pubmedid: 33867192.
  • Reblin M, Ketcher D, McCormick R, Barrios-Monroy V, Sutton SK, Zebrack B, Wells KJ, Sahebjam S, Forsyth P, Byrne MM. A randomized wait-list controlled trial of a social support intervention for caregivers of patients with primary malignant brain tumor. BMC Health Serv Res. 2021 Apr.21(1):360. Pubmedid: 33865382. Pmcid: PMC8052543.
  • Ellingson BM, Sampson JH, Achrol AS, Aghi MK, Krystof Bankiewicz K, Wang C, Bexon M, Brem S, Brenner AJ, Chowdhary S, Floyd JR, Han SJ, Kesari S, Randazzo D, Vogelbaum MA, Vrionis FD, Zabek M, Butowski N, Coello M, Merchant N, Merchant F. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. Clin Cancer Res. 2021 Apr. Pubmedid: 33863808.
  • Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Apr. Pubmedid: 33864019.
  • Tafreshi NK, Kil H, Pandya DN, Tichacek CJ, Doligalski ML, Budzevich MM, Delva NC, Langsen ML, Vallas JA, Boulware DC, Engelman RW, Gage KL, Moros EG, Wadas TJ, McLaughlin ML, Morse DL. Lipophilicity Determines Routes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting Peptide Receptor Radiotherapy. ACS Pharmacol Transl Sci. 2021 Apr.4(2):953-965. Pubmedid: 33860213. Pmcid: PMC8033749.
  • Sadler D, Arnold A, Herrmann J, Daniele A, Silva CMPDC, Ghosh AK, Szmit S, Khan RI, Raez L, Blaes A, Brown SA. Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building. Curr Oncol Rep. 2021 Apr.23(6):64. Pubmedid: 33855620. Pmcid: PMC8045572.
  • Dineen SP, Pimiento JM. The Landmark Series: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for Treatment of Gastric Cancer Metastatic to Peritoneum. Ann Surg Oncol. 2021 Apr. Pubmedid: 33856601.
  • Fazio N, Carnaghi C, Buzzoni R, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel ME, Yao JC. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Cancer. 2021 Apr. Pubmedid: 33857327.
  • Kim MP, Li X, Deng J, Zhang Y, Dai B, Allton KL, Hughes TG, Siangco C, Augustine JJ, Kang Y, McDaniel JM, Xiong S, Koay EJ, McAllister F, Bristow CA, Heffernan TP, Maitra A, Liu B, Barton MC, Wasylishen AR, Fleming JB, Lozano G. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov. 2021 Apr. Pubmedid: 33839689.
  • Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Apr.19(4):439-457. Pubmedid: 33845462.
  • Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A. 2021 Apr.118(15). Pubmedid: 33827917. Pmcid: PMC8053941.
  • Lee EQ, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, Chang SM, de Groot JF, Galanis E, Hassan I, Kalidas C, Khasraw M, Kvedar JC, Lassman AB, Puduvalli V, Sahebjam S, Schwamm LH, Tamir S, Welch M, Yung WKA, Zadeh G, Arons D, Wen PY. Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience. Neurooncol. 2021 Apr. Pubmedid: 33822177. Pmcid: PMC8083574.
  • Kunigelis KE, Vogelbaum MA. Therapeutic Delivery to Central Nervous System. Neurosurg Clin N Am. 2021 Apr.32(2):291-303. Pubmedid: 33781509.
  • Wilkes JG, Patel A, McClure E, Pina Y, Zager JS. Developments in therapy for brain metastases in melanoma patients. Expert Opin Pharmacother. 2021 Apr.1-11. Pubmedid: 33688795.
  • Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Inv Drug. 2021 Apr.30(4):451-461. Pubmedid: 33660569.
  • Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Googe PB, Carson CC, McKinnon K, Wang HH, Nikolaishvilli-Feinberg N, Ivanova A, Arrowood CC, Garrett-Mead N, Conway KC, Edmiston SN, Ollila DW, Serody JS, Thomas NE, Ivy SP, Agrawal L, Dees EC, Abbruzzese JL. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). Melanoma Res. 2021 Apr.31(2):162-172. Pubmedid: 33661190. Pmcid: PMC8025369.
  • Kuykendall AT, Tokumori FC, Komrokji RS. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes. Hematol Oncol Clin North Am. 2021 Apr.35(2):337-352. Pubmedid: 33641873.
  • Jain RK, Ross JS, Necchi A, Spiess PE. Should Upper-tract Urothelial Carcinoma and Bladder Carcinoma Be Treated the Same or Different?. Eur Urol Oncol. 2021 Apr.4(2):180-181. Pubmedid: 33602655.
  • Otvos B, Alban TJ, Grabowski MM, Bayik D, Mulkearns-Hubert EE, Radivoyevitch T, Rabljenovic A, Johnson S, Androjna C, Mohammadi AM, Barnett GH, Ahluwalia MS, Vogelbaum MA, Fecci PE, Lathia JD. Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome. Clin Cancer Res. 2021 Apr.27(7):2038-2049. Pubmedid: 33542075. Pmcid: PMC8026586.
  • Chan O, Komrokji RS. Luspatercept in the treatment of lower-risk myelodysplastic syndromes. Future Oncol. 2021 Apr.17(12):1473-1481. Pubmedid: 33511859.
  • Belizaire R, Koochaki SHJ, Udeshi ND, Vedder A, Sun L, Svinkina T, Hartigan C, McConkey ME, Kovalcik V, Bizuayehu A, Stanclift C, Schenone M, Carr SA, Padron E, Ebert BL. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. Blood. 2021 Apr.137(16):2209-2220. Pubmedid: 33512474. Pmcid: PMC8063090.
  • Richardson DR, Swoboda DM, Moore DT, Johnson SM, Chan O, Galeotti J, Esparza S, Hussaini MO, Van Deventer H, Foster MC, Coombs CC, Montgomery ND, Sallman DA, Zeidner JF. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia. Am J Hematol. 2021 Apr.96(4):462-470. Pubmedid: 33502020.
  • Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res. 2021 Apr.10(5):343-352. Pubmedid: 33442996.
  • Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming JB, Anaya DA. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol. 2021 Apr.28(4):1939-1949. Pubmedid: 33415559.
  • Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Mol Ther. 2021 Apr.29(4):1541-1556. Pubmedid: 33412308. Pmcid: PMC8058490.
  • Sahin IH, Tan E, Kim R. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opin Inv Drug. 2021 Apr.30(4):333-341. Pubmedid: 33378249.
  • Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
  • Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E, Kolasińska-Ćwikła A, Zandee WT, Laskaratos FM, de Mestier L, Lamarca A, Hernando J, Cwikla JB, Strosberg J, de Herder WW, Caplin M, Cives M, van Leeuwaarde RS. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?. Oncologist. 2021 Apr.26(4):294-301. Pubmedid: 33301235. Pmcid: PMC8018333.
  • Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, Kim RD. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer. 2021 Apr.127(8):1293-1300. Pubmedid: 33289918.
  • Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
  • Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada AM, Jacob AT, Kinahan C, Francescone M, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes DL, Scotto L, Sokol L, Shustov AR, O'Connor OA. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021 Apr.137(16):2161-2170. Pubmedid: 33171487.
  • Saeed H, Sokol L. Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens. Clin Lymphoma Myeloma Leuk. 2021 Apr.21(4):199-204. Pubmedid: 33129745.
  • Alwelaie Y, Point du Jour KS, Pandya S, Goodman AL, Centeno BA, Adsay V, Reid MD. Acinar cell induced autolysis is a frequent occurrence in CytoLyt-fixed pancreatic fine needle aspiration specimens: An analysis of 157 cytology samples. Cancer Cytopathol. 2021 Apr.129(4):283-290. Pubmedid: 33136337.
  • Zhang C, Smalley I, Emmons MF, Sharma R, Izumi V, Messina J, Koomen JM, Pasquale EB, Forsyth PA, Smalley KSM. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma. J Invest Dermatol. 2021 Apr.141(4):840-851.e4. Pubmedid: 32890629. Pmcid: PMC7921215.
  • Daou H, Hatch LA, Weinkle A, Morey GE, Messina J, Zhang X, Sokol L, Seminario-Vidal L. CD8-positive cutaneous lymphoproliferation associated with large granular lymphocyte leukemia in a patient with X-linked agammaglobulinemia. J Cutan Pathol. 2021 Apr.48(4):567-571. Pubmedid: 32885480.
  • Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021 Apr.35(4):1145-1155. Pubmedid: 32728186. Pmcid: PMC7854836.
  • Broman KK, Baez H, Mihelic E, Zhu S, Dineen S, Fleming JB, Anaya DA, Pimiento JM. Combined use of advanced practice providers and care pathways reduces the duration of stay after surgery for gastrointestinal malignancies. Surgery. 2021 Apr.169(4):852-858. Pubmedid: 32713756.
  • Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
  • Thompson JF, Haydu LE, Uren RF, Andtbacka RH, Zager JS, Beitsch PD, Agnese DM, Mozzillo N, Testori A, Bowles TL, Hoekstra HJ, Kelley MC, Sussman J, Schneebaum S, Smithers BM, McKinnon G, Hsueh E, Jacobs L, Schultz E, Reintgen D, Kane JM, Friedman EB, Wang H, Van Kreuningen L, Schiller V, Elashoff DA, Elashoff R, Cochran AJ, Stern S, Faries MB. Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial. Ann Surg. 2021 Apr.273(4):814-820. Pubmedid: 31188198.
  • Zaman S, Hajiran A, Coba GA, Robinson T, Madanayake TW, Segarra DT, Chobrutskiy BI, Boyle TA, Zhou JM, Kim Y, Mulé JJ, Teer JK, Manley BJ. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. Eur Urol Focus. 2021 Mar.7(2):373-380. Pubmedid: 31901438. Pmcid: PMC7771328.
  • Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. Am Soc Clin Oncol Educ Book. 2021 Mar.41:1-23. Pubmedid: 33979196.
  • Jardim-Perassi BV, Mu W, Huang S, Tomaszewski MR, Poleszczuk J, Abdalah MA, Budzevich MM, Dominguez-Viqueira W, Reed DR, Bui MM, Johnson JO, Martinez GV, Gillies RJ. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma. Theranostics. 2021 Mar.11(11):5313-5329. Pubmedid: 33859749. Pmcid: PMC8039958.
  • Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, McGraw KL, Moon J, Murphy DJ, Ballabio A, Kaufmann SH, Berglund AE, Cleveland JL. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021 Mar.2(2):162-185. Pubmedid: 33860275. Pmcid: PMC8043621.
  • Mason NT, Burkett JM, Nelson RS, Pow-Sang JM, Gatenby RA, Kubal T, Peabody JW, Letson GD, McLeod HL, Zhang J. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2021 Mar.14(1):15-20. Pubmedid: 33841621. Pmcid: PMC8025923.
  • Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, Masannat J, Song F, Hernandez-Prera JC, Wenig BM, Molina H, Farinhas JM, McMullen CP, Wadsworth JT, Patel KB, Kish JA, Muzaffar J, Kirtane K, Rocco JW, Schell MJ, Saba NF. Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. Cancers (Basel). 2021 Mar.13(5). Pubmedid: 33803335. Pmcid: PMC7967147.
  • Ahmad SB, Rice M, Chang C, Hamad A, Kingham TP, He J, Pimiento JM, Zureikat AH, Zeh HJ, Hogg ME. Will It Play in Peoria? A Pilot Study of a Robotic Skills Curriculum for Surgical Oncology Fellows. Ann Surg Oncol. 2021 Mar. Pubmedid: 33791900.
  • Robinson LA, Fontaine J, El-Haddad G, Bryant S, Perez B, Toloza E, Kis B. Novel Subdiaphragmatic Ligation of Left Thoracic Duct for Refractory Postoperative Left Chylothorax. Ann Thorac Surg. 2021 Mar. Pubmedid: 33794166.
  • Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
  • Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526.
  • Strosberg JR, Srirajaskanthan R, El-Haddad G, Wolin EM, Chasen BR, Kulke MH, Bushnell DL, Caplin ME, Baum RP, Hendifar AE, Öberg K, Ruszniewski P, Santoro P, Broberg P, Leeuwenkamp OR, Krenning EP. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE. J Nucl Med. 2021 Mar. Pubmedid: 33771903.
  • Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, Engelman RW, Boulware DC, Chiappori AA, Strosberg JR, Ji H, Wadas TJ, El-Haddad G, Morse DL. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021 Mar. Pubmedid: 33772332.
  • Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Ne. 2021 Mar.1-8. Pubmedid: 33761455.
  • Lara H, Li Z, Abels E, Aeffner F, Bui MM, ElGabry EA, Kozlowski C, Montalto MC, Parwani AV, Zarella MD, Bowman D, Rimm D, Pantanowitz L. Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association. Appl Immunohistochem Mol Morphol. 2021 Mar. Pubmedid: 33734106.
  • Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 Mar.5(6):1719-1728. Pubmedid: 33724305. Pmcid: PMC7993093.
  • Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021 Mar.34(11):108870. Pubmedid: 33730585. Pmcid: PMC8057695.
  • Saller J, Jiang K, Xiong Y, Yoder SJ, Neill K, Pimiento JM, Pena L, Corbett FS, Magliocco A, Coppola D. A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer. Digest Dis Sci. 2021 Mar. Pubmedid: 33713247.
  • Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 Mar.5(6):1648-1659. Pubmedid: 33710337. Pmcid: PMC7993097.
  • Qayyum A, Bhosale P, Aslam R, Avritscher R, Ma J, Pagel MD, Sun J, Mohamed Y, Rashid A, Beretta L, Kaseb AO. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY). 2021 Mar.46(3):1008-1015. Pubmedid: 32974761. Pmcid: PMC8191337.
  • Ragheb J, Mony S, Klapman J, Erim T, Reagan A, Butler R, Dong Y, Cruise M, Centeno BA, Bejarano P, Stevens T, Hayat U, Bhatt A. Impact of margin status on outcomes after endoscopic resection of well-differentiated duodenal neuroendocrine tumors. Gastrointest Endosc. 2021 Mar. Pubmedid: 33676923.
  • Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 Mar.11(3):52. Pubmedid: 33677472. Pmcid: PMC7936977.
  • Grove O, Berglund AE, Schabath MB, Aerts HJWL, Dekker A, Wang H, Velazquez ER, Lambin P, Gu Y, Balagurunathan Y, Eikman E, Gatenby RA, Eschrich S, Gillies RJ. Correction: Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma. PLoS One. 2021 Mar.16(3):e0248541. Pubmedid: 33684181. Pmcid: PMC7939347.
  • Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021 Mar.21(1):223. Pubmedid: 33663447. Pmcid: PMC7934378.
  • Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Mar. Pubmedid: 33658647.
  • Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Mar. Pubmedid: 33658659.
  • Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 Mar.22(3):e105-e118. Pubmedid: 33662288.
  • Tolaney SM, Sahebjam S, Rhun EL, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer. Clin Cancer Res. 2021 Mar.27(5):1582. Pubmedid: 33649192.
  • Tengesdal IW, Menon DR, Osborne DG, Neff CP, Powers NE, Gamboni F, Mauro AG, D'Alessandro A, Stefanoni D, Henen MA, Mills TS, De Graaf DM, Azam T, Vogeli B, Palmer BE, Pietras EM, DeGregori J, Tan AC, Joosten LAB, Fujita M, Dinarello CA, Marchetti C. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. Proc Natl Acad Sci U S A. 2021 Mar.118(10). Pubmedid: 33649199. Pmcid: PMC7958415.
  • Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar.10(6):1936-1943. Pubmedid: 33641257. Pmcid: PMC7957158.
  • Shields MD, Hicks JK, Boyle TA, Haura EB, Creelan BC. Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib. J Thorac Oncol. 2021 Mar.16(3):e15-e17. Pubmedid: 33641722.
  • Konidaris G, Paul E, Kuznik A, Keeping S, Chen CI, Sasane M, Xu Y, Atsou K, Ayers D, Ruiz ES, Khushalani NI, Cope S. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. Value Health. 2021 Mar.24(3):377-387. Pubmedid: 33641772.
  • Shi LL, McMullen C, Vorwald K, Nichols AC, MacNeil SD, Wadsworth JT, Chung CH, Wang X, Patel KB. Survival outcomes of patients with subglottic squamous cell carcinoma : a study of the National Cancer Database. Eur Arch Otorhinolaryngol. 2021 Mar. Pubmedid: 33646344.
  • Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
  • Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer. 2021 Mar.28(3):R81-R93. Pubmedid: 33608483. Pmcid: PMC8118168.
  • Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021 Mar.146:56-73. Pubmedid: 33588146.
  • Lee JC, Hong KH, Becker A, Tash JS, Schönbrunn E, Georg GI. Tetrahydroindazole inhibitors of CDK2/cyclin complexes. Eur J Med Chem. 2021 Mar.214:113232. Pubmedid: 33550184. Pmcid: PMC7954990.
  • Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 Mar.591(7850):464-470. Pubmedid: 33536615. Pmcid: PMC7969354.
  • Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol. 2021 Mar.39(9):956-965. Pubmedid: 33507809. Pmcid: PMC8078254.
  • Miroshnychenko D, Baratchart E, Ferrall-Fairbanks MC, Velde RV, Laurie MA, Bui MM, Tan AC, Altrock PM, Basanta D, Marusyk A. Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations. Nat Ecol Evol. 2021 Mar.5(3):379-391. Pubmedid: 33462489.
  • Deveaux AE, Allen TA, Al Abo M, Qin X, Zhang D, Patierno BM, Gu L, Gray JE, Pecot CV, Dressman HK, McCall SJ, Kittles RA, Hyslop T, Owzar K, Crawford J, Patierno SR, Clarke JM, Freedman JA. RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. Lung Cancer. 2021 Mar.153:90-98. Pubmedid: 33465699. Pmcid: PMC8049647.
  • Visweshwar N, Jaglal M, Patel A, Laber D, Sokol L. Should we integrate viscoelastic assays with standard coagulation screening?. J Clin Pathol. 2021 Mar.74(3):141-143. Pubmedid: 33436484.
  • List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, Litzow MR, Tallman MS. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. J Clin Oncol. 2021 Mar.39(9):1001-1009. Pubmedid: 33439748.
  • Bertino EM, Gentzler RD, Clifford SE, Kolesar JM, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann CL, Malhotra J, Villaruz LC, Paweletz CP, Lau CJ, Sholl LM, Takebe N, Moscow JA, Shapiro GI, Janne PA, Oxnard GR. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 Mar.27(6):1604-1611. Pubmedid: 33376097. Pmcid: PMC7976451.
  • Neelature Sriramareddy S, Smalley KSM. MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma. Clin Cancer Res. 2021 Mar.27(5):1217-1219. Pubmedid: 33355300. Pmcid: PMC7925419.
  • Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Ferrucci PF, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol. 2021 Mar.32(3):384-394. Pubmedid: 33309774.
  • Sun L, Zhang X, Song Q, Liu L, Forbes E, Tian W, Zhang Z, Kang Y, Wang H, Fleming JB, Pasche BC, Zhang W. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Lett. 2021 Mar.500:132-146. Pubmedid: 33309859. Pmcid: PMC7923838.
  • Divgi C, Carrasquillo JA, Meredith R, Seo Y, Frey EC, Bolch WE, Zimmerman BE, Akabani G, Jacobson DA, Brown B, Davern SM, Hobbs RF, Humm J, Moros EG, Morse D, Papineni R, Zanzonico P, Benedict SH, Sgouros G. Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. Int J Radiat Oncol Biol Phys. 2021 Mar.109(4):905-912. Pubmedid: 33309909.
  • Scott JG, Sedor G, Scarborough JA, Kattan MW, Peacock J, Grass GD, Mellon EA, Thapa R, Schell M, Waller A, Poppen S, Andl G, Teer J, Eschrich SA, Dilling TJ, Dalton WS, Harrison LB, Fox T, Torres-Roca JF. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. J Thorac Oncol. 2021 Mar.16(3):428-438. Pubmedid: 33301984.
  • Xie H, Kim RD. The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. Ann Surg Oncol. 2021 Mar.28(3):1845-1858. Pubmedid: 32776184.
  • Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neurooncol. 2021 Mar.23(3):457-467. Pubmedid: 32678879. Pmcid: PMC7992874.
  • Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
  • Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021 Mar.35(3):835-849. Pubmedid: 32595214. Pmcid: PMC7932916.
  • Aulakh S, Reljic T, Yassine F, Ayala E, Chavez JC, Chanan-Khan A, Pinilla-Ibarz J, Kumar A, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021 Mar.14(1):33-40. Pubmedid: 32473105. Pmcid: PMC7666647.
  • Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
  • Katzman JH, Tahmasbi M, Ghayouri M, Nanjappa S, Li MC, Greene J. Management of Severe Hidradenitis Suppurativa. Cureus. 2021 Feb.13(2):e13483. Pubmedid: 33777570. Pmcid: PMC7989970.
  • Renduchintala K, Nanjappa S, Ramsakal A, Greene J. Successful Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus Necrotizing Pneumonia in the Setting of Chronic Graft-Versus-Host Disease. Cureus. 2021 Feb.13(2):e13123. Pubmedid: 33728140. Pmcid: PMC7935285.
  • Elgarten CW, Li Y, Getz KD, Hemmer M, Huang YV, Hall M, Wang T, Kitko CL, Jagasia MH, Nishihori T, Murthy HS, Hashem H, Cairo MS, Sharma A, Hashmi SK, Askar M, Beitinjaneh A, Kelly MS, Auletta JJ, Badawy SM, Mavers M, Aplenc R, MacMillan ML, Spellman SR, Arora M, Fisher BT. Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. Transplant Cell Ther. 2021 Feb.27(2):177.e1-177.e8. Pubmedid: 33718896. Pmcid: PMC7946150.
  • Kim E, Brown JS, Eroglu Z, Anderson ARA. Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33669315. Pmcid: PMC7920057.
  • Permuth JB, Dezsi KB, Vyas S, Ali KN, Basinski TL, Utuama OA, Denbo JW, Klapman J, Dam A, Carballido E, Kim DW, Pimiento JM, Powers BD, Otto AK, Choi JW, Chen DT, Teer JK, Beato F, Ward A, Cortizas EM, Whisner SY, Williams IE, Riner AN, Tardif K, Velanovich V, Karachristos A, Douglas WG, Legaspi A, Allan BJ, Meredith K, Molina-Vega MA, Bao P, St Julien J, Huguet KL, Green L, Odedina FT, Kumar NB, Simmons VN, George TJ, Vadaparampil ST, Hodul PJ, Arnoletti JP, Awad ZT, Bose D, Jiang K, Centeno BA, Gwede CK, Malafa M, Judge SM, Judge AR, Jeong D, Bloomston M, Merchant NB, Fleming JB, Trevino JG. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. Cancers (Basel). 2021 Feb.13(4). Pubmedid: 33671939. Pmcid: PMC7919015.
  • Al-Toubah T, Grozinsky-Glasberg S, Strosberg J. An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH). CURR TREAT OPTION ON. 2021 Feb.22(4):28. Pubmedid: 33641079.
  • Vogelbaum MA, Parney IF, Elder JB, Cahill D. Neurosurgical involvement in clinical trials for CNS tumors. J Neurooncol. 2021 Feb.151(3):367-373. Pubmedid: 33611704.
  • D'Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. Convection-enhanced drug delivery for glioblastoma: a review. J Neurooncol. 2021 Feb.151(3):415-427. Pubmedid: 33611708. Pmcid: PMC8034832.
  • Lu S, Dhillon J, Johnson JH, El-Haddad G. Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology. EJNMMI Res. 2021 Feb.11(1):17. Pubmedid: 33604708. Pmcid: PMC7892660.
  • Mazin A, Hawkins SH, Stringfield O, Dhillon J, Manley BJ, Jeong DK, Raghunand N. Identification of sarcomatoid differentiation in renal cell carcinoma by machine learning on multiparametric MRI. Sci Rep. 2021 Feb.11(1):3785. Pubmedid: 33589715. Pmcid: PMC7884398.
  • Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021 Feb.5(4):1017-1028. Pubmedid: 33591325. Pmcid: PMC7903224.
  • Davis RR, Li B, Yun SY, Chan A, Nareddy P, Gunawan S, Ayaz M, Lawrence HR, Reuther GW, Lawrence NJ, Schönbrunn E. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. J Med Chem. 2021 Feb.64(4):2228-2241. Pubmedid: 33570945.
  • Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021 Feb.5(4):975-983. Pubmedid: 33576783. Pmcid: PMC7903230.
  • Teras J, Carr MJ, Zager JS, Kroon HM. Molecular Aspects of the Isolated Limb Infusion Procedure. Biomedicines. 2021 Feb.9(2). Pubmedid: 33562337. Pmcid: PMC7915579.
  • Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 Feb.50(2):130-137. Pubmedid: 33560090.
  • Lin HY, Wang X, Tseng TS, Kao YH, Fang Z, Molina PE, Cheng CH, Berglund AE, Eeles RA, Muir KR, Pashayan N, Haiman CA, Brenner H, Consortium TP, Park JY. Alcohol Intake and Alcohol-SNP Interactions Associated with Prostate Cancer Aggressiveness. J Clin Med. 2021 Feb.10(3). Pubmedid: 33540941. Pmcid: PMC7867322.
  • Hathaway CA, Siegel EM, Chung CH, Pabbathi S, Vidrine J, Vadaparampil S, Tworoger SS. Utilizing a large-scale biobanking registry to assess patient priorities and preferences for cancer research and education. PLoS One. 2021 Feb.16(2):e0246686. Pubmedid: 33544776. Pmcid: PMC7864448.
  • Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, Oberstein P, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein S. Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncol Pract. 2021 Feb.OP2000701. Pubmedid: 33534616.
  • McGuire JJ, Frieling JS, Lo CH, Li T, Muhammad A, Lawrence HR, Lawrence NJ, Cook LM, Lynch CC. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer. Nat Commun. 2021 Feb.12(1):723. Pubmedid: 33526787. Pmcid: PMC7851397.
  • Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, Kaivers J, Ungerstedt J, Heibl S, Patiou P, Hunter AM, Mora E, Geissler K, Dimou M, Jimenez Lorenzo MJ, Melchardt T, Egle A, Viniou AN, Patel BJ, Arnan M, Valent P, Roubakis C, Bernal Del Castillo T, Galanopoulos A, Calabuig Muñoz M, Bonadies N, Medina de Almeida A, Cermak J, Jerez A, Montoro MJ, Cortés A, Avendaño Pita A, Lopez Andrade B, Hellstroem-Lindberg E, Germing U, Sekeres MA, List AF, Symeonidis A, Sanz GF, Larcher-Senn J, Greil R. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021 Feb.8(2):e135-e148. Pubmedid: 33513373.
  • Pelle E, Al-Toubah T, Morse B, El-Haddad G, Strosberg J. Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. J Neuroendocrinol. 2021 Feb.33(2):e12936. Pubmedid: 33474756.
  • Chaudhary R, Slebos RJC, Song F, McCleary-Sharpe KP, Masannat J, Tan AC, Wang X, Amaladas N, Wu W, Hall GE, Conejo-Garcia JR, Hernandez-Prera JC, Chung CH. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Mol Carcinogen. 2021 Feb.60(2):138-150. Pubmedid: 33378592. Pmcid: PMC7856233.
  • Hui JYC, Burke E, Broman KK, Marmor S, Jensen E, Tuttle TM, Zager JS. Surgeon decision-making for management of positive sentinel lymph nodes in the post-Multicenter Selective Lymphadenectomy Trial II era: A survey study. J Surg Oncol. 2021 Feb.123(2):646-653. Pubmedid: 33289125. Pmcid: PMC7902320.
  • Liu W, Chan CM, Gong L, Bui MM, Han G, Letson GD, Yang Y, Niu X. Malignancy in giant cell tumor of bone in the extremities. J Bone Oncol. 2021 Feb.26:100334. Pubmedid: 33251099. Pmcid: PMC7680773.
  • Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R, Sharfman W, Atkins M, Spigel DR, Pavlick A, Monzon J, Kim KB, Ernst S, Khushalani NI, van Dijck W, Lobo M, Hogg D. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021 Feb.31(1):67-75. Pubmedid: 33234846. Pmcid: PMC7757740.
  • Al-Toubah T, Morse B, Pelle E, Strosberg J. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. Oncologist. 2021 Feb.26(2):115-119. Pubmedid: 33225478. Pmcid: PMC7873336.
  • Soliman H, Hogue D, Han HS, Mooney B, Lima Barros Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Rosa M, Khong H, Czerniecki BJ. A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Feb.27(4):1012-1018. Pubmedid: 33219014.
  • Sachdev JC, Munster P, Northfelt DW, Han HS, Ma C, Maxwell F, Wang T, Belanger B, Zhang B, Moore Y, Thiagalingam A, Anders C. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Res Treat. 2021 Feb.185(3):759-771. Pubmedid: 33201358. Pmcid: PMC7921078.
  • Yamoah K, Lal P, Awasthi S, Naghavi AO, Rounbehler RJ, Gerke T, Berglund AE, Pow-Sang JM, Schaeffer EM, Dhillon J, Park JY, Rebbeck TR. TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. Prostate. 2021 Feb.81(2):109-117. Pubmedid: 33141952. Pmcid: PMC7810127.
  • Alsina M, Landgren O, Raje N, Niesvizky R, Bensinger WI, Berdeja JG, Kovacsovics T, Vesole DH, Fang B, Kimball AS, Siegel DS. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Am J Hematol. 2021 Feb.96(2):226-233. Pubmedid: 33125764. Pmcid: PMC7898514.
  • Morton JJ, Alzofon N, Keysar SB, Chimed TS, Reisinger J, Perrenoud L, Le PN, Nieto C, Gomez K, Miller B, Yeager R, Gao D, Tan AC, Somerset H, Medina T, Wang XJ, Wang JH, Robinson W, Roop DR, Gonzalez R, Jimeno A. Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. Mol Cancer Res. 2021 Feb.19(2):346-357. Pubmedid: 33087417. Pmcid: PMC7864867.
  • Camacho-Bydume C, Wang T, Sees JA, Fernandez-Viña M, Abid MB, Askar M, Beitinjaneh A, Brown V, Castillo P, Chharbra S, Gadalla SM, Hsu JM, Kamoun M, Lazaryan A, Nishihori T, Page K, Schetelig J, Fleischhauer K, Marsh SGE, Paczesny S, Spellman SR, Lee SJ, Hsu KC. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transplant Cell Ther. 2021 Feb.27(2):142.e1-142.e11. Pubmedid: 33053450. Pmcid: PMC8015676.
  • Beato F, Reverón D, Dezsi KB, Ortiz A, Johnson JO, Chen DT, Ali K, Yoder SJ, Jeong D, Malafa M, Hodul P, Jiang K, Centeno BA, Abdalah MA, Balasi JA, Tassielli AF, Sarcar B, Teer JK, DeNicola GM, Permuth JB, Fleming JB. Establishing a living biobank of patient-derived organoids of intraductal papillary mucinous neoplasms of the pancreas. Lab Invest. 2021 Feb.101(2):204-217. Pubmedid: 33037322. Pmcid: PMC7855435.
  • Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543.
  • Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
  • Bandini M, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres B, Hakenberg OW, Heidenreich A, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. Eur Urol Oncol. 2021 Feb.4(1):121-123. Pubmedid: 32943378.
  • Han D, Han G, Duque MT, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS. Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. Ann Surg Oncol. 2021 Feb.28(2):1007-1016. Pubmedid: 32524460.
  • Carraway S, Martin S, Greene JN. Preventing the Spread: A Comprehensive Cancer Center's Journey to Prevent the Spread of Coronavirus Disease (Covid-19) During the 2020 Pandemic. Cancer Control. 2021 Jan.28. Pubmedid: 34044598. Pmcid: PMC8204456.
  • Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS. Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO Precis Oncol. 2021 Jan.5. Pubmedid: 34036237. Pmcid: PMC8140814.
  • Gopalakrishnan D, Jain RK, Herbst L, Sikorski M, Mandava S, Azabdaftari G, Xu B, LeVea C, Robillard K, Ernstoff MS, George S. Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma. Front Oncol. 2021 Apr.11:679177. Pubmedid: 33996609. Pmcid: PMC8117341.
  • Tantawy M, Chekka LM, Huang Y, Garrett TJ, Singh S, Shah CP, Cornell RF, Baz RC, Fradley MG, Waheed N, DeRemer DL, Yuan L, Langaee T, March K, Pepine CJ, Moreb JS, Gong Y. Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Front Cardiovasc Med. 2021 Apr.8:645122. Pubmedid: 33996940. Pmcid: PMC8116486.
  • Hutchinson T, Hoffe S, Saeed S, Pflanzer SA, Fleming JB, Pabbathi S. Gastrointestinal Disease-Specific Survivorship Care: A New Personalized Model Integrating Onco-Wellness. Cancer Control. 2021 Jan.28. Pubmedid: 33926264. Pmcid: PMC8204645.
  • Law V, Baldwin M, Ramamoorthi G, Kodumudi K, Tran N, Smalley I, Duckett D, Kalinski P, Czerniecki B, Smalley KSM, Forsyth PA. A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. J Vis Exp. 2021 Jan.(167). Pubmedid: 33586709.
  • Khouri J, Faiman BM, Grabowski D, Mahfouz RZ, Khan SN, Wei W, Valent J, Dean R, Samaras C, Jha BK, Lazarus H, Campagnaro EL, Malek E, Reed J, Karam MA, Hamilton K, Fada S, Kalaycio M, Liu H, Sobecks R, Saunthararajah Y, Chew Y, Orloff M, Reu FJ. DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Semin Hematol. 2021 Jan.58(1):45-55. Pubmedid: 33509443.
  • Anaya DA, Dogra P, Wang Z, Haider M, Ehab J, Jeong DK, Ghayouri M, Lauwers GY, Thomas K, Kim R, Butner JD, Nizzero S, Ramírez JR, Plodinec M, Sidman RL, Cavenee WK, Pasqualini R, Arap W, Fleming JB, Cristini V. A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases. Cancers (Basel). 2021 Jan.13(3). Pubmedid: 33503971. Pmcid: PMC7866038.
  • Volpe VO, Komrokji RS. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?. Ther Adv Hematol. 2021 Jan.12. Pubmedid: 33505645. Pmcid: PMC7812395.
  • Husain K, Coppola D, Yang CS, Malafa MP. Farnesyl dimethyl chromanol targets colon cancer stem cells and prevents colorectal cancer metastasis. Sci Rep. 2021 Jan.11(1):2185. Pubmedid: 33500430. Pmcid: PMC7838198.
  • Muzaffar J, Bari S, Kirtane K, Chung CH. Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2021 Jan.13(2). Pubmedid: 33477635. Pmcid: PMC7831487.
  • Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. 2021 Jan. Pubmedid: 33480358.
  • Malachowski SJ, Moy A, Messina J, Chen YA, Sun J, Sokol L, Seminario-Vidal L. Mapping cutaneous T-cell lymphoma in the state of Florida: A retrospective exploratory spatial analysis of incidence patterns. J Am Acad Dermatol. 2021 Jan. Pubmedid: 33476732.
  • Phadke M, Ozgun A, Eroglu Z, Smalley KSM. Melanoma brain metastases: Biological basis and novel therapeutic strategies. Exp Dermatol. 2021 Jan. Pubmedid: 33455008.
  • Wang MY, Li T, Ren Y, Shah BD, Lwin T, Gao J, Shain KH, Zhang W, Zhao X, Tao J. MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas. Blood Cancer J. 2021 Jan.11(1):14. Pubmedid: 33446629. Pmcid: PMC7809345.
  • Ruiz-Deya G, Matta J, Encarnación-Medina J, Ortiz-Sanchéz C, Dutil J, Putney R, Berglund A, Dhillon J, Kim Y, Park JY. Differential DNA Methylation in Prostate Tumors from Puerto Rican Men. Int J Mol Sci. 2021 Jan.22(2). Pubmedid: 33450964. Pmcid: PMC7828429.
  • Zhang J, Cunningham JJ, Brown JS, Gatenby RA. Response to Mistry. Nat Commun. 2021 Jan.12(1):329. Pubmedid: 33436553. Pmcid: PMC7804311.
  • Gibbs JD, Ma S, Kim A, Seminario-Vidal L, Sokol L, Zhang H, Zhang X, Sagatys E, Chen PL, Messina JL. Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma. Oncol Rep. 2021 Jan.45(1):349-358. Pubmedid: 33416132.
  • Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Ne. 2021 Jan.19(1):16-27. Pubmedid: 33406488.
  • Yang X, Yin H, Kim RD, Fleming JB, Xie H. Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective. Target Oncol. 2021 Jan.16(1):1-12. Pubmedid: 33369705.
  • Komrokji RS, Al Ali NH, Sallman D, Padron E, DeZern AE, Barnard J, Roboz GJ, Garcia-Manero G, List A, Steensma DP, Sekeres MA. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Med. 2021 Jan.10(2):447-453. Pubmedid: 33350168. Pmcid: PMC7877342.
  • Hartnett S, Kroll D, Vogelbaum MA. Surgical Adjuncts for Glioblastoma. Neurosurg Clin N Am. 2021 Jan.32(1):83-91. Pubmedid: 33223029.
  • Vogelbaum MA. Surgical Management of Glioblastoma: More Than Just Diagnosis and Decompression. Neurosurg Clin N Am. 2021 Jan.32(1):xiii-xxiv. Pubmedid: 33223032.
  • Martín-Broto J, Lopez Pousa A, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 Jan.20(1):132-141. Pubmedid: 33177152.
  • Mariotti V, Han H, Ismail-Khan R, Tang SC, Dillon P, Montero AJ, Poklepovic A, Melin S, Ibrahim NK, Kennedy E, Vahanian N, Link C, Tennant L, Schuster S, Smith C, Danciu O, Gilman P, Soliman H. Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021 Jan.7(1):61-69. Pubmedid: 33151286. Pmcid: PMC7645745.
  • Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, Sallman DA, Komrokji RS. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021 Jan.35(1):286-288. Pubmedid: 33132383.
  • Schwabkey ZI, Al Ali N, Chan O, Sallman DA, Padron E, Kuykendall AT, Talati C, Sweet K, Lancet JE, Komrokji RS. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clin Lymphoma Myeloma Leuk. 2021 Jan.21(1):e52-e56. Pubmedid: 33093008.
  • He T, Wildey G, McColl K, Savadelis A, Spainhower K, McColl C, Kresak A, Tan AC, Yang M, Abbas A, Dowlati A. Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer. Mol Oncol. 2021 Jan.15(1):195-209. Pubmedid: 33084222. Pmcid: PMC7782087.
  • Awasthi S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, Kensler KH, Serna AN, Vidal AC, You S, Freeman MR, Davicioni E, Liu Y, Karnes JR, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk SP, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 Jan.27(1):320-329. Pubmedid: 33037017. Pmcid: PMC8042600.
  • Ibrahim-Hashim A, Luddy K, Abrahams D, Enriquez-Navas P, Damgaci S, Yao J, Chen T, Bui MM, Gillies RJ, O'Farrelly C, Richards CL, Brown JS, Gatenby RA. Artificial selection for host resistance to tumour growth and subsequent cancer cell adaptations: an evolutionary arms race. Brit J Cancer. 2021 Jan.124(2):455-465. Pubmedid: 33024265. Pmcid: PMC7852689.
  • Gong L, Bui MM, Zhang W, Sun X, Zhang M, Yi D. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors. Histol Histopathol. 2021 Jan.36(1):61-68. Pubmedid: 33021329.
  • Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier B, Litzow M, Kebriaei P, Saber W, Weisdorf D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Ma. Transplant Cell Ther. 2021 Jan.27(1):68.e1-68.e9. Pubmedid: 33010430. Pmcid: PMC8015679.
  • Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arruabarrena-Aristorena A, Kittane S, Wu F, Cai Y, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, Novoplansky O, Jagadeeshan S, Liao Y, Rix U, Misale S, Taylor BS, Bardelli A, Hechtman JF, Hyman DM, Elkabets M, de Stanchina E, Verma CS, Ventura A, Drilon A, Scaltriti M. TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discov. 2021 Jan.11(1):126-141. Pubmedid: 33004339. Pmcid: PMC8012405.
  • Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat Rev Clin Oncol. 2021 Jan.18(1):56-62. Pubmedid: 32918064.
  • Liu J, Peng Y, Shi L, Wan L, Inuzuka H, Long J, Guo J, Zhang J, Yuan M, Zhang S, Wang X, Gao J, Dai X, Furumoto S, Jia L, Pandolfi PP, Asara JM, Kaelin WG, Liu J, Wei W. Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Res. 2021 Jan.31(1):104. Pubmedid: 32859994. Pmcid: PMC7852582.
  • Ketcher DE, Bidelman A, Le LQ, Otto AK, Lester DK, Amtmann-Beuttner KK, Gonzalez B, Wright KL, Vadaparampil ST, Reblin M, Lau EK. Partnering patients, caregivers, and basic scientists: an engagement model that fosters patient- and family-centered research culture. Transl Res. 2021 Jan.227:64-74. Pubmedid: 32739418. Pmcid: PMC7719089.
  • Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021 Jan.31(1):36-49. Pubmedid: 32689909. Pmcid: PMC7864115.
  • Liu J, Peng Y, Shi L, Wan L, Inuzuka H, Long J, Guo J, Zhang J, Yuan M, Zhang S, Wang X, Gao J, Dai X, Furumoto S, Jia L, Pandolfi PP, Asara JM, Kaelin WG, Liu J, Wei W. Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Res. 2021 Jan.31(1):80-93. Pubmedid: 32669607. Pmcid: PMC7852548.
  • Strosberg JR, Al-Toubah T, Pellè E, Smith J, Haider M, Hutchinson T, Fleming JB, El-Haddad G. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. J Nucl Med. 2021 Jan.62(1):69-72. Pubmedid: 32444368.
  • Powers BD, Rothermel LD, Fleming JB, Strosberg JR, Anaya DA. A Survival Analysis of Patients with Localized, Asymptomatic Pancreatic Neuroendocrine Tumors: No Surgical Survival Benefit when Examining Appropriately Selected Outcomes. J Gastrointest Surg. 2020 Dec.24(12):2773-2779. Pubmedid: 31754990.
  • Renduchintala K, Pabbathi S, Nanjappa S, Ramsakal A, Greene J. A Case of Alpha-1 Antitrypsin Deficiency and Organizing Pneumonia. Cureus. 2020 Dec.12(12):e12078. Pubmedid: 33489496. Pmcid: PMC7805524.
  • Grisaru-Tal S, Itan M, Grass DG, Torres-Roca J, Eschrich SA, Gordon Y, Dolitzky A, Hazut I, Avlas S, Jacobsen EA, Ziv-Baran T, Munitz A. Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations. Oncoimmunology. 2020 Dec.10(1):1859732. Pubmedid: 33457078. Pmcid: PMC7781846.
  • Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. Cancer Treat Rev. 2020 Dec.93:102141. Pubmedid: 33418096.
  • Nwagwu CD, Immidisetti AV, Bukanowska G, Vogelbaum MA, Carbonell AM. Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec.13(1). Pubmedid: 33396712. Pmcid: PMC7823464.
  • Dulgar O, Kutuk T, Eroglu Z. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies. Am J Clin Dermatol. 2020 Dec.22(1):1-10. Pubmedid: 33368052.
  • Chandrachud PP, Wojtas L, Lopchuk JM. Decarboxylative Amination: Diazirines as Single and Double Electrophilic Nitrogen Transfer Reagents. J Am Chem Soc. 2020 Dec.142(52):21743-21750. Pubmedid: 33332115.
  • Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Dec.18(12):1685-1717. Pubmedid: 33285522.
  • Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2020 Dec. Pubmedid: 33303244.
  • Tadesse S, Duckett DR, Monastyrskyi A. The promise and current status of CDK12/13 inhibition for the treatment of cancer. Future Med Chem. 2021 Jan.13(2):117-141. Pubmedid: 33295810.
  • Kaushik G, Seshacharyulu P, Rauth S, Nallasamy P, Rachagani S, Nimmakayala RK, Vengoji R, Mallya K, Chirravuri-Venkata R, Singh AB, Foster JM, Ly QP, Smith LM, Lele SM, Malafa MP, Jain M, Ponnusamy MP, Batra SK. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Oncogene. 2020 Dec.40(4):848-862. Pubmedid: 33288882. Pmcid: PMC7848971.
  • von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Meyer C, Pappo AS, Parkes AM, Paz IB, Petersen IA, Poppe M, Riedel RF, Rubin B, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Bergman MA, George GV. NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. J Natl Compr Canc Ne. 2020 Dec.18(12):1604-1612. Pubmedid: 33285515.
  • Swoboda DM, Sallman DA. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies. Best Pract Res Clin Haematol. 2020 Dec.33(4):101221. Pubmedid: 33279177.
  • Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum J, Clarke BN, Coleman N, Dewaraja YK, Frey EC, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos C, Larson SM, Lin FI, Madsen MT, Mirzadeh S, Morse DL, Pryma DA, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico PB, Zukotynski KB. Overview of the First NRG-NCI Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy (RPT). J Nucl Med. 2020 Dec. Pubmedid: 33277396.
  • Harro CM, Perez-Sanz J, Costich TL, Payne KK, Anadon Galindo CM, Chaurio RA, Biswas S, Mandal G, Rigolizzo KE, Sprenger KB, Mine JA, Showe L, Yu X, Liu K, Rodriguez PC, Pinilla-Ibarz J, Sokol L, Conejo-Garcia JR. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. J Clin Invest. 2020 Dec.131(3). Pubmedid: 33270606. Pmcid: PMC7843215.
  • Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, Tomaszewski MR, Latifi K, Pimiento JM, Fontaine JP, Mehta R, Harrison LB, Hoffe SE, Frakes JM. Pretreatment CT and 18 F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer. J Med Imaging Radiat Oncol. 2020 Dec.65(1):102-111. Pubmedid: 33258556.
  • Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Komrokji R, Steensma D, Balleari E, Götze KS, Kotsianidis I, Guerci-Bresler A, Stamatoullas A, Sanz GF, Germing U, Fenaux P. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leuk Res. 2020 Dec.99:106472. Pubmedid: 33212326.
  • Shao H, Wang W, Song J, Tang G, Zhang X, Tang Z, Srivastava J, Shah B, Medeiros LJ, Zhang L. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. Leuk Res. 2020 Dec.99:106460. Pubmedid: 33166908.
  • Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao A, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 Dec.6(12):1939-1946. Pubmedid: 33119048. Pmcid: PMC7596685.
  • Maller B, Bigness A, Moiño D, Greene J. Sweet's syndrome associated with hematological malignancies. Leuk Res. 2020 Dec.99:106461. Pubmedid: 33099235.
  • Kim DW, Schell MJ, Kim RD. Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer-Reply. JAMA Oncol. 2020 Dec.6(12):1981-1982. Pubmedid: 33090188.
  • Turner JG, Cui Y, Bauer AA, Dawson JL, Gomez JA, Kim J, Cubitt CL, Nishihori T, Dalton WS, Sullivan DM. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma. Cancer Res. 2020 Dec.80(23):5344-5354. Pubmedid: 33023948. Pmcid: PMC7718436.
  • Hernandez MC, Leiting JL, Joshi VB, Yang L, Leong H, Thomas RM, Fleming J, Truty MJ. Patient-derived xenografts in surgical oncology: A short research review. Surgery. 2020 Dec.168(6):1021-1025. Pubmedid: 33010939.
  • Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 Dec.126(23):5077-5087. Pubmedid: 32965680. Pmcid: PMC8063213.
  • Carr MJ, Sun J, Kroon HM, Miura JT, Beasley GM, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Kirichenko DA, Potdar A, Daou H, Mullen D, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Coventry BJ, Tyler DS, Thompson JF, Zager JS. Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. Ann Surg Oncol. 2020 Dec.27(13):5107-5118. Pubmedid: 32918177. Pmcid: PMC7674259.
  • Carr MJ, Kroon HM, Zager JS. ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma. Ann Surg Oncol. 2020 Dec.27(13):5119-5120. Pubmedid: 32918180.
  • Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 Dec.15(12):1919-1927. Pubmedid: 32916308.
  • Simmons VN, Sutton SK, Meltzer LR, Martinez U, Palmer AM, Meade CD, Jacobsen PB, McCaffrey JC, Haura EB, Brandon TH. Preventing smoking relapse in patients with cancer: A randomized controlled trial. Cancer. 2020 Dec.126(23):5165-5172. Pubmedid: 32902856. Pmcid: PMC7771373.
  • Skelton WP, Turba E, Sokol L. Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e944-e946. Pubmedid: 32828719.
  • Xie H, Kim RD. ASO Author Reflections: Clinical Utility of Circulating Tumor DNA Analysis in Colorectal Cancer: Current Status. Ann Surg Oncol. 2020 Dec.27(Suppl 3):890. Pubmedid: 32812106.
  • Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e956-e960. Pubmedid: 32778513.
  • Kim R, Tan E, Wang E, Mahipal A, Chen DT, Cao B, Masawi F, Machado C, Yu J, Kim DW. A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. Oncologist. 2020 Dec.25(12):e1893-e1899. Pubmedid: 32776632. Pmcid: PMC8186409.
  • Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020 Dec.136(24):2812-2823. Pubmedid: 32730593. Pmcid: PMC7731792.
  • Vogelzang NJ, Olsen MR, McFarlane JJ, Arrowsmith E, Bauer TM, Jain RK, Somer B, Lam ET, Kochenderfer MD, Molina A, Doshi G, Lingerfelt B, Hauke RJ, Gunuganti V, Schnadig I, Van Veldhuizen P, Fleming M, Galamaga R, Gupta M, Hool H, Hutson T, Zhang J, McHenry MB, Johansen JL, Tykodi SS. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer. 2020 Dec.18(6):461-468.e3. Pubmedid: 32718906.
  • Okten IN, Ismail S, Withycombe BM, Eroglu Z. Preclinical discovery and clinical development of encorafenib for the treatment of melanoma. Expert Opin Drug Discov. 2020 Dec.15(12):1373-1380. Pubmedid: 32720533.
  • Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 Dec.61(12):2811-2820. Pubmedid: 32662346.
  • McFarlane JJ, Kochenderfer MD, Olsen MR, Bauer TM, Molina A, Hauke RJ, Reeves JA, Babu S, Van Veldhuizen P, Somer B, Gunuganti V, Schnadig I, George S, Page RD, Arrowsmith E, Jain RK, Zhang J, McHenry MB, Johansen JL, Vogelzang NJ. Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clin Genitourin Cancer. 2020 Dec.18(6):469-476.e4. Pubmedid: 32641261.
  • Lee AY, Friedman EB, Sun J, Potdar A, Daou H, Farrow NE, Farley CR, Vetto JT, Han D, Tariq M, Shapiro R, Beasley G, Contreras CM, Osman I, Lowe M, Zager JS, Berman RS. The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. Ann Surg Oncol. 2020 Dec.27(13):5259-5266. Pubmedid: 32529271.
  • Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 Dec.34(12):3338-3347. Pubmedid: 32313109. Pmcid: PMC7572530.
  • Yin Q, Wyatt CJ, Han T, Smalley KSM, Wan L. ITCH as a potential therapeutic target in human cancers. Semin Cancer Biol. 2020 Dec.67(Pt 2):117-130. Pubmedid: 32165318. Pmcid: PMC7724637.
  • Mu W, Liang Y, Hall LO, Tan Y, Balagurunathan Y, Wenham R, Wu N, Tian J, Gillies RJ. 18F-FDG PET/CT Habitat Radiomics Predicts Outcome of Patients with Cervical Cancer Treated with Chemoradiotherapy. Radiol Artif Intell. 2020 Nov.2(6):e190218. Pubmedid: 33937845. Pmcid: PMC8082355.
  • Sadler D, DeCara JM, Herrmann J, Arnold A, Ghosh AK, Abdel-Qadir H, Yang EH, Szmit S, Akhter N, Leja M, Silva CMPDC, Raikhelkar J, Brown SA, Dent S, O'Quinn R, Thuny F, Moudgil R, Raez LE, Okwuosa T, Daniele A, Bauer B, Kondapalli L, Ismail-Khan R, Lax J, Blaes A, Nahleh Z, Elson L, Baldassarre LA, Zaha V, Rao V, Lara DS, Skurka K. Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey. Cardiooncology. 2020 Nov.6(1):28. Pubmedid: 33292763. Pmcid: PMC7691954.
  • Makovich Z, Logemann J, Chen L, Mhaskar R, Choi J, Parikh N, El-Haddad G, Kis B. Liver tumor ablation in difficult locations: Microwave ablation of perivascular and subdiaphragmatic hepatocellular carcinoma. Clin Imaging. 2020 Nov.71:170-177. Pubmedid: 33285405.
  • Garg SK, Welsh EA, Fang B, Hernandez YI, Rose T, Gray J, Koomen JM, Berglund A, Mulé JJ, Markowitz J. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers (Basel). 2020 Nov.12(12). Pubmedid: 33255891. Pmcid: PMC7768436.
  • Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv. 2020 Nov.4(22):5716-5721. Pubmedid: 33216886. Pmcid: PMC7686903.
  • Bandini M, Ross JS, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres BA, Hakenberg OW, Heidenreich A, Salvioni R, Catanzaro M, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, Briganti A, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. Eur Urol Oncol. 2020 Nov. Pubmedid: 33199252.
  • Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 Nov.8(2). Pubmedid: 33199512. Pmcid: PMC7670953.
  • Pointer DT, Saeed S, Naffouje SA, Mehta R, Hoffe SE, Dineen SP, Fleming JB, Fontaine JP, Pimiento JM. Outcomes of 350 Robotic-assisted Esophagectomies at a High-volume Cancer Center: A Contemporary Propensity-score Matched Analysis. Ann Surg. 2020 Nov. Pubmedid: 33201093.
  • Cives M, Pelle' E, Strosberg J. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. J Clin Med. 2020 Nov.9(11). Pubmedid: 33202931. Pmcid: PMC7696369.
  • Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020 Nov.21(1):271. Pubmedid: 33148332. Pmcid: PMC7640699.
  • Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler JS, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve DC, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow SD. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Nov.18(11):1537-1570. Pubmedid: 33152694.
  • Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Ne. 2020 Nov.18(11):1460-1467. Pubmedid: 33152703.
  • Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, Coombs CC, Caltabellotta NM, Walsh M, Offit K, Stadler Z, Mandelker D, Schulman J, Patel A, Philip J, Bernard E, Gundem G, Ossa JEA, Levine M, Martinez JSM, Farnoud N, Glodzik D, Li S, Robson ME, Lee C, Pharoah PDP, Stopsack KH, Spitzer B, Mantha S, Fagin J, Boucai L, Gibson CJ, Ebert BL, Young AL, Druley T, Takahashi K, Gillis N, Ball M, Padron E, Hyman DM, Baselga J, Norton L, Gardos S, Klimek VM, Scher H, Bajorin D, Paraiso E, Benayed R, Arcila ME, Ladanyi M, Solit DB, Berger MF, Tallman M, Garcia-Closas M, Chatterjee N, Diaz LA, Levine RL, Morton LM, Zehir A, Papaemmanuil E. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genetics. 2020 Nov.52(11):1219-1226. Pubmedid: 33106634. Pmcid: PMC7891089.
  • Berglund A, Amankwah EK, Kim YC, Spiess PE, Sexton WJ, Manley B, Park HY, Wang L, Chahoud J, Chakrabarti R, Yeo CD, Luu HN, Pietro GD, Parker A, Park JY. Influence of gene expression on survival of clear cell renal cell carcinoma. Cancer Med. 2020 Nov.9(22):8662-8675. Pubmedid: 32986937. Pmcid: PMC7666730.
  • Tichacek CJ, Tafreshi NK, Kil H, Engelman RW, Doligalski ML, Budzevich MM, Gage KL, McLaughlin ML, Wadas TJ, Silva A, Moros E, Morse DL. Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy. Mol Pharm. 2020 Nov.17(11):4180-4188. Pubmedid: 32960613.
  • Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 Nov.21(11):1465-1477. Pubmedid: 32961119.
  • Yassine F, Iqbal M, Murthy H, Kharfan-Dabaja MA, Chavez JC. Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Curr Res Transl Med. 2020 Nov.68(4):159-170. Pubmedid: 32811793.
  • Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Nov.38(32):3763-3772. Pubmedid: 32795228. Pmcid: PMC7655021.
  • Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Tr. 2020 Nov.26(11):2139-2146. Pubmedid: 32781289. Pmcid: PMC7609542.
  • Brierley CK, Zabor EC, Komrokji RS, DeZern AE, Roboz GJ, Brunner AM, Stone RM, Sekeres MA, Steensma DP. Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer. 2020 Nov.126(21):4735-4743. Pubmedid: 32767690.
  • Kenyon-Smith TJ, Kroon HM, Miura JT, Teras J, Beasley GM, Mullen D, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Potdar A, Daou H, Sun J, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Barbour A, Coventry BJ, Tyler DS, Zager JS, Thompson JF. Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. Eur J Surg Oncol. 2020 Nov.46(11):2140-2146. Pubmedid: 32739218.
  • Prager BC, Vasudevan HN, Dixit D, Bernatchez JA, Wu Q, Wallace LC, Bhargava S, Lee D, King BH, Morton AR, Gimple RC, Pekmezci M, Zhu Z, Siqueira-Neto JL, Wang X, Xie Q, Chen C, Barnett GH, Vogelbaum MA, Mack SC, Chavez L, Perry A, Raleigh DR, Rich JN. The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies. Cancer Discov. 2020 Nov.10(11):1722-1741. Pubmedid: 32703768. Pmcid: PMC8194360.
  • Ward B, Wang C, Macaulay RJB, Liu JKC. Adult Intracranial Myxoid Mesenchymal Tumor with EWSR1-ATF1 Gene Fusion. World Neurosurg. 2020 Nov.143:91-96. Pubmedid: 32683005.
  • Kim JK, DePeralta DK, Ogami T, Denbo JW, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Powers BD. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. J Surg Oncol. 2020 Nov.122(6):1074-1083. Pubmedid: 32673436.
  • Reljic T, Sehovic M, Lancet J, Kim J, Al Ali N, Djulbegovic B, Extermann M. Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis. Geriatr Oncol. 2020 Nov.11(8):1293-1308. Pubmedid: 32665186. Pmcid: PMC7864384.
  • Vogelbaum MA, Krivosheya D, Borghei-Razavi H, Sanai N, Weller M, Wick W, Soffietti R, Reardon DA, Aghi MK, Galanis E, Wen PY, van den Bent M, Chang S. Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. Neurooncol. 2020 Nov.22(11):1568-1579. Pubmedid: 32598442. Pmcid: PMC7690357.
  • Komrokji RS, Ali NA, Sallman D, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. 2020 Nov.34(11):3097-3099. Pubmedid: 32565544.
  • Piakong P, Kiatisevi P, Yau R, Trovarelli G, Lam YL, Joyce D, Ruggieri P, Temple HT, Letson D, Binitie O. What Is the 10-year Survivorship of Cemented Distal Femoral Endoprostheses for Tumor Reconstructions and What Radiographic Features Are Associated with Survival?. Clin Orthop Relat Res. 2020 Nov.478(11):2573-2581. Pubmedid: 32469487. Pmcid: PMC7594923.
  • Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 Nov.38(33):3947-3970. Pubmedid: 32228358.
  • Al-Toubah T, Pelle E, Strosberg J. What is the role of checkpoint inhibitors in neuroendocrine neoplasms?. Oncotarget. 2020 Oct.11(42):3751-3752. Pubmedid: 33144916. Pmcid: PMC7584236.
  • Taylor NJ, Gaynanova I, Eschrich SA, Welsh EA, Garrett TJ, Beecher C, Sharma R, Koomen JM, Smalley KSM, Messina JL, Kanetsky PA. Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment. PLoS One. 2020 Oct.15(10):e0240849. Pubmedid: 33108391. Pmcid: PMC7591037.
  • Thor AD, Wahdan-Alaswad RS, Edgerton SM, Salem H, Kim H, Tan AC, Finlay-Schultz J, Wellberg E, Sartorius CA, Jacobsen BM, Haugen BR, Liu B. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. Clin Cancer Res. 2021 Jan.27(2):585-597. Pubmedid: 33097494.
  • Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 Oct.5(5):e000799. Pubmedid: 33097651. Pmcid: PMC7590373.
  • Chung R, Tyebally S, Chen D, Kapil V, Walker JM, Addison D, Ismail-Khan R, Guha A, Ghosh AK. Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology. J Clin Med. 2020 Oct.9(10). Pubmedid: 33081013. Pmcid: PMC7603211.
  • Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 Oct.8(2). Pubmedid: 33051340. Pmcid: PMC7555111.
  • Padron E. Toward classifying the unclassifiable. Blood. 2020 Oct.136(16):1800-1801. Pubmedid: 33057699.
  • Di L, Huang K, Kesayan T, Kroll D, Baz RC, Macaulay RJ, Tran ND. Multiple myeloma presenting as an intramedullary spinal cord tumor: a case report and review of the literature. J Med Case Rep. 2020 Oct.14(1):189. Pubmedid: 33059729. Pmcid: PMC7566029.
  • Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat Commun. 2020 Oct.11(1):5228. Pubmedid: 33067442. Pmcid: PMC7567795.
  • Al-Toubah T, Cives M, Strosberg J. Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. Transl Gastroenterol Hepatol. 2020 Oct.5:54. Pubmedid: 33073049. Pmcid: PMC7530319.
  • Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, Yao JC, Nejati R, Cai KQ, Caruso LB, Swatler J, Dabrowski M, Lian Z, Valent P, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, Huang J, Challen GA, Link D, Tempera I, Wasik MA, Piwocka K, Skorski T. TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. Cell Rep. 2020 Oct.33(1):108221. Pubmedid: 33027668. Pmcid: PMC7578922.
  • Asamoah FA, Yarney J, Scott A, Vanderpuye V, Yuan Z, Fernandez DC, Montejo ME, Agyeman M, Boateng SN, Anarfi K, Aidoo C, Shahzad MM, Chern JY, Chon HS, Wenham RM, Yamoah K, Ahmed KA. Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment. JCO Glob Oncol. 2020 Oct.6:1510-1518. Pubmedid: 33021855. Pmcid: PMC7605379.
  • Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, Litzow M, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, Solh M, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. Blood Adv. 2020 Oct.4(19):4748-4757. Pubmedid: 33007075. Pmcid: PMC7556156.
  • Liu JKC. Initial Approach to Patients with a Newly Diagnosed Solitary Brain Metastasis. Neurosurg Clin N Am. 2020 Oct.31(4):489-503. Pubmedid: 32921346.
  • Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct.21(10):1269-1282. Pubmedid: 32861273.
  • Darville LNF, Cline JK, Rozmeski C, Martinez YC, Rich S, Eschrich SA, Egan KM, Yaghjyan L, Koomen JM. LC-HRMS of derivatized urinary estrogens and estrogen metabolites in postmenopausal women. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct.1154:122288. Pubmedid: 32769047. Pmcid: PMC7882395.
  • Whisenant MS, Williams LA, Garcia Gonzalez A, Mendoza T, Shi Q, Cleeland C, Zhang J, Heymach J, Simon G. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 Oct.16(10):e1151-e1160. Pubmedid: 32539654.
  • Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 Oct.25(10):e1457-e1463. Pubmedid: 32608142. Pmcid: PMC7543335.
  • Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel, Diefenbach C. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Oncologist. 2020 Oct.25(10):878-885. Pubmedid: 32720734. Pmcid: PMC7543382.
  • Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Diéras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 Oct.26(20):5310-5319. Pubmedid: 32694159.
  • Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of. J Thorac Oncol. 2020 Oct.15(10):1577-1598. Pubmedid: 32663527.
  • Jayasekera J, Vadaparampil ST, Eggly S, Street RL, Foster Moore T, Isaacs C, Han HS, Augusto B, Garcia J, Lopez K, O'Neill SC. Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes. JCO Oncol Pract. 2020 Oct.16(10):e1085-e1097. Pubmedid: 32463763. Pmcid: PMC7564130.
  • Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Brit J Haematol. 2020 Oct.191(1):44-51. Pubmedid: 32430944.
  • Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, Guba SC, Capper D, Rodon J. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Invest New Drugs. 2020 Oct.38(5):1570-1579. Pubmedid: 32140889. Pmcid: PMC7497674.
  • Boyle TA, Khalil FK, Mino-Kenudson M, Sica GL, Moreira AL, Sholl LM, Knight MZ, Zhang L, Saller J, Varella-Garcia M, Berry LD, Chen H, Ellison KE, Rivard CJ, Kugler K, Wistuba II, Fujimoto J, Kwiatkowski DJ, Bunn PA, Kris MG, Haura EB, Hirsch FR. Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance. Appl Immunohistochem Mol Morphol. 2020 Oct.28(9):669-677. Pubmedid: 31876606. Pmcid: PMC7242128.
  • Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma. 2020 Sep.7:143-153. Pubmedid: 32984091. Pmcid: PMC7502406.
  • Diaz LI, Mony S, Klapman J. Narrative review of the role of gastroenterologist in the diagnosis, treatment and palliation in gastric and gastroesophageal cancer. Ann Transl Med. 2020 Sep.8(17):1106. Pubmedid: 33145325. Pmcid: PMC7575985.
  • Dam AN, Klapman J. A narrative review of Barrett's esophagus in 2020, molecular and clinical update. Ann Transl Med. 2020 Sep.8(17):1107. Pubmedid: 33145326. Pmcid: PMC7575938.
  • Mitchell JR, Kamnitsas K, Singleton KW, Whitmire SA, Clark-Swanson KR, Ranjbar S, Rickertsen CR, Johnston SK, Egan KM, Rollison DE, Arrington J, Krecke KN, Passe TJ, Verdoorn JT, Nagelschneider AA, Carr CM, Port JD, Patton A, Campeau NG, Liebo GB, Eckel LJ, Wood CP, Hunt CH, Vibhute P, Nelson KD, Hoxworth JM, Patel AC, Chong BW, Ross JS, Boxerman JL, Vogelbaum MA, Hu LS, Glocker B, Swanson KR. Deep neural network to locate and segment brain tumors outperformed the expert technicians who created the training data. J Med Imaging (Bellingham). 2020 Sep.7(5):055501. Pubmedid: 33102623. Pmcid: PMC7567400.
  • Khadilkar AC, Adashek JJ, Riddle ND, Sokol L. Primary Cutaneous Gamma/Delta T-cell Lymphoma and Hemophagocytic Lymphohistiocytosis Associated With AIDS. Cureus. 2020 Sep.12(9):e10386. Pubmedid: 33062507. Pmcid: PMC7549995.
  • Hunter AM, Padron E. Molecular genetics of MDS/MPN overlap syndromes. Best Pract Res Clin Haematol. 2020 Sep.33(3):101195. Pubmedid: 33038984.
  • Saeed SM, Naffouje S, Mehta R, Hoffe SE, Fontaine JP, Lauwers GY, Shah P, Frakes J, Pimiento JM. Impact of histology classification on pathologic treatment response and overall survival in distal esophageal cancer patients: a propensity matched analysis. Dis Esophagus. 2020 Sep. Pubmedid: 32996568.
  • Chai AWY, Yee PS, Price S, Yee SM, Lee HM, Tiong VK, Gonçalves E, Behan FM, Bateson J, Gilbert J, Tan AC, McDermott U, Garnett MJ, Cheong SC. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. Elife. 2020 Sep.9. Pubmedid: 32990596. Pmcid: PMC7591259.
  • Jain RK, Skelton WP, Zhang J. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin. Cancer Manag Res. 2020 Sep.12:8379-8386. Pubmedid: 32982431. Pmcid: PMC7494003.
  • Centeno BA. Metastases, Secondary Tumors, and Lymphomas of the Pancreas. Monogr Clin Cytol. 2020 Sep.26:109-121. Pubmedid: 32987382.
  • Centeno BA, Thomas SC. Non-Neoplastic and Neoplastic Cysts of the Pancreas. Monogr Clin Cytol. 2020 Sep.26:53-73. Pubmedid: 32987387.
  • Morse B, Klapman J. Imaging of Pancreatic Tumors. Monogr Clin Cytol. 2020 Sep.26:21-33. Pubmedid: 32987388.
  • Centeno BA, Dhillon J. Preface. Monogr Clin Cytol. 2020 Sep.26:VI-VII. Pubmedid: 32987392.
  • Centeno BA, Thomas SC. Non-Neoplastic Masses of the Pancreas. Monogr Clin Cytol. 2020 Sep.26:42-52. Pubmedid: 32987396.
  • Mahipal A, Tella SH, Kommalapati A, Yu J, Kim R. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020 Nov.155:103091. Pubmedid: 32961472.
  • Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Pusceddu S, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncol. 2020 Sep.16(27):2089-2099. Pubmedid: 32938212.
  • Lin TA, Eroglu Z, Carvajal R, Markowitz J. Cohort Identification for Translational Bioinformatics Studies. Methods Mol Biol. 2020 Sep.2194:35-44. Pubmedid: 32926360. Pmcid: PMC7787345.
  • Berglund AE, Putney RM, Creed JH, Aden-Buie G, Gerke TA, Rounbehler RJ. Accessible Pipeline for Translational Research Using TCGA: Examples of Relating Gene Mechanism to Disease-Specific Outcomes. Methods Mol Biol. 2020 Sep.2194:127-142. Pubmedid: 32926365.
  • Stewart PA, Welsh EA, Fang B, Izumi V, Mesa T, Zhang C, Yoder S, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Avedon M, Wloch M, Fournier M, Fellows KM, Francis JM, Saller JJ, Boyle TA, Chen YA, Haura EB, Teer JK, Eschrich SA, Koomen JM. Managing a Large-Scale Multiomics Project: A Team Science Case Study in Proteogenomics. Methods Mol Biol. 2020 Sep.2194:187-221. Pubmedid: 32926368. Pmcid: PMC7771375.
  • O'Neill SC, Vadaparampil ST, Street RL, Moore TF, Isaacs C, Han HS, Augusto B, Garcia J, Lopez K, Brilleman M, Jayasekera J, Eggly S. Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar. Patient Educ Couns. 2021 Feb.104(2):250-256. Pubmedid: 32900604. Pmcid: PMC7854933.
  • Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, Öberg K, Modlin IM. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020 Sep.21(9):e431-e443. Pubmedid: 32888472.
  • Gerds AT, Gotlib J, Bose P, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Sep.18(9):1248-1269. Pubmedid: 32886902.
  • Kuykendall AT, Komrokji R. What's in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia. J Natl Compr Canc Ne. 2020 Sep.18(9):1279-1284. Pubmedid: 32886905.
  • Afiat TN, Hembree TN, Dean EA, Araujo C, Pena LR, Rosa M, Han HS, Hendrix K, Ramsakal A. Diffuse Intrasinusoidal Hepatic Metastasis from Breast Cancer Presenting as Liver Failure: Effective and Rapid Treatment with Weekly Low-Dose Adriamycin. Am J Case Rep. 2020 Sep.21:e924141. Pubmedid: 32877389. Pmcid: PMC7491943.
  • Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: 32877523. Pmcid: PMC7479945.
  • Lorza AMA, Ravi H, Philip RC, Galons JP, Trouard TP, Parra NA, Von Hoff DD, Read WL, Tibes R, Korn RL, Raghunand N. Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin. Sci Rep. 2020 Sep.10(1):14449. Pubmedid: 32879326. Pmcid: PMC7468301.
  • Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Ne. 2020 Sep.1-4. Pubmedid: 32871558.
  • Sallman DA. The Problem of TP53-Mutant MDS/AML. Clin Lymphoma Myeloma Leuk. 2020 Sep.20 Suppl 1:S65-S66. Pubmedid: 32862873.
  • Haura EB, Hicks JK, Boyle TA. Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib. J Thorac Oncol. 2020 Sep.15(9):e154-e156. Pubmedid: 32854916.
  • Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, Yao J, Engelman RW, Creelan BC, Conejo-Garcia JR, Antonia SJ, Mulé JJ, Kim S. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. Cell Metab. 2020 Sep.32(3):420-436.e12. Pubmedid: 32768387. Pmcid: PMC7484212.
  • Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 Sep.15(9):1449-1459. Pubmedid: 32389639.
  • Elmeliegy M, Den Haese J, Talati C, Wetzler M, Jusko WJ. Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia. Cancer Chemother Pharmacol. 2020 Sep.86(3):325-337. Pubmedid: 32748108. Pmcid: PMC7539618.
  • Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. 2020 Sep.6(9):1355-1362. Pubmedid: 32701140. Pmcid: PMC7378873.
  • Karakousis G, Sondak VK, Zager JS. Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. J Clin Oncol. 2020 Sep.38(27):3234-3235. Pubmedid: 32701416.
  • Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
  • Krzyston H, Morse B, Deperalta D, Rishi A, Kayaleh R, El-Haddad G, Smith J, Druta M, Kis B. Liver-directed treatments of liver-dominant metastatic leiomyosarcoma. Diagn Interv Radiol. 2020 Sep.26(5):449-455. Pubmedid: 32673206. Pmcid: PMC7490031.
  • Wang X, Yu X, Krauthammer M, Hugo W, Duan C, Kanetsky PA, Teer JK, Thompson ZJ, Kalos D, Tsai KY, Smalley KSM, Sondak VK, Chen YA, Conejo-Garcia JR. The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev. 2020 Sep.29(9):1792-1799. Pubmedid: 32611582. Pmcid: PMC7483810.
  • Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clin Cancer Res. 2020 Sep.26(18):4767-4776. Pubmedid: 32611648.
  • Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, Rivard C, Yu H, Finigan JH, Dowlati A, Rudin CM, Tan AC. Role of mTOR As an Essential Kinase in SCLC. J Thorac Oncol. 2020 Sep.15(9):1522-1534. Pubmedid: 32599072. Pmcid: PMC7483946.
  • Zamarin D, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall MA, Hong DS. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clin Cancer Res. 2020 Sep.26(17):4531-4541. Pubmedid: 32586937.
  • Iwanaga R, Truong BT, Hsu JY, Lambert KA, Vyas R, Orlicky D, Shellman YG, Tan AC, Ceol C, Artinger KB. Loss of prdm1a accelerates melanoma onset and progression. Mol Carcinogen. 2020 Sep.59(9):1052-1063. Pubmedid: 32562448. Pmcid: PMC7864383.
  • Hashmi H, Nishihori T. Role of hematopoietic cell transplantation in relapsed acute promyelocytic leukemia. Clin Transplant. 2020 Sep.34(9):e14009. Pubmedid: 32526047.
  • Henderson ER, Keeney BJ, Husson EG, Bernthal NM, Ji T, Pala E, Funovics PT, Groundland JS, Lozano-Calderon S, Puchner S, Zoller SD, Ruggieri P, Windhager R, Guo W, Hornicek FJ, Letson GD, Temple HT. Nonmechanical Revision Indications Portend Repeat Limb-Salvage Failure Following Total Femoral Replacement. J Bone Joint Surg Am. 2020 Sep.102(17):1511-1520. Pubmedid: 32453111.
  • Hsieh JK, Colby S, Nichols D, Kondylis E, Liu JKC. Delayed Development of Spinal Subdural Hematoma Following Cranial Trauma: A Case Report and Review of the Literature. World Neurosurg. 2020 Sep.141:44-51. Pubmedid: 32450315.
  • Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 Sep.26(17):4633-4642. Pubmedid: 32414750. Pmcid: PMC7864382.
  • Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020 Sep.38(27):3119-3128. Pubmedid: 32401634. Pmcid: PMC7499611.
  • Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 Sep.20(9):e597-e605. Pubmedid: 32303488.
  • Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
  • Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 Sep.47(10):2372-2382. Pubmedid: 32123969. Pmcid: PMC7396396.
  • Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 Sep.34(9):2430-2440. Pubmedid: 32094461. Pmcid: PMC7449872.
  • Balbona J, Chen L, Malafa MP, Hodul PJ, Dineen SP, Mehta R, Mhaskar RS, Pimiento JM. Outcomes of Gastric Resection in the Establishment of a Comprehensive Oncologic Robotic Program. J Surg Res. 2020 Aug.252:30-36. Pubmedid: 32222591.
  • Patnaik MM, Sallman DA, Mangaonkar A, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020 Aug.136(7):909-913. Pubmedid: 32294158. Pmcid: PMC7531999.
  • Bayik D, Zhou Y, Park C, Hong C, Vail D, Silver DJ, Lauko A, Roversi G, Watson DC, Lo A, Alban TJ, McGraw M, Sorensen M, Grabowski MM, Otvos B, Vogelbaum MA, Horbinski C, Kristensen BW, Khalil AM, Hwang TH, Ahluwalia MS, Cheng F, Lathia JD. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. Cancer Discov. 2020 Aug.10(8):1210-1225. Pubmedid: 32300059. Pmcid: PMC7415660.
  • Duong VH, Al Ali N, Zhang L, Padron E, Sallman D, Lancet JE, List AF, Komrokji RS. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Leuk Lymphoma. 2020 Aug.61(8):1901-1907. Pubmedid: 32306798.
  • Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes T, Orlowski RZ, Shain KH, Cowan AJ, Murphy SP, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin T, Richardson PG. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug.136(8):936-945. Pubmedid: 32325490. Pmcid: PMC7441167.
  • Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM, Kulikauskas R, Chung CH, Martens UM, Ferris RL, Stein JE, Engle EL, Devriese LA, Lao CD, Gu J, Li B, Chen T, Barrows A, Horvath A, Taube JM, Nghiem P. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. J Clin Oncol. 2020 Aug.38(22):2476-2487. Pubmedid: 32324435. Pmcid: PMC7392746.
  • Patnaik MM, Lasho T, Padron E, McCullough K, Al-Kali A, Tefferi A, Zeidan AM, Gangat N, Savona M, Steensma DP, Solary E. Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. Am J Hematol. 2020 Aug.95(8):E203-E208. Pubmedid: 32356322. Pmcid: PMC7267346.
  • Hesterberg RS, Beatty MS, Han Y, Fernandez MR, Akuffo AA, Goodheart WE, Yang C, Chang S, Colin C, Alontaga AY, McDaniel J, Mailloux AW, Billington JMR, Yue L, Russell S, Gillies RJ, Yun SY, Ayaz M, Lawrence NJ, Lawrence H, Yu XZ, Fu J, Darville LN, Koomen JM, Ren X, Messina J, Jiang K, Garrett TJ, Rajadhyaksha A, Cleveland JL, Epling-Burnette PK. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes. Blood. 2020 Aug.136(7):857-870. Pubmedid: 32403132. Pmcid: PMC7426646.
  • Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, Solh M, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Tr. 2020 Aug.26(8):1459-1468. Pubmedid: 32434056. Pmcid: PMC7391266.
  • Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Mol Cancer Ther. 2020 Aug.19(8):1623-1635. Pubmedid: 32430484. Pmcid: PMC7415672.
  • Kim RD, Sanoff HK, Poklepovic AS, Soares H, Kim J, Lyu J, Liu Y, Nixon AB, Kim DW. A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 2020 Aug.126(15):3464-3470. Pubmedid: 32453456. Pmcid: PMC7787270.
  • Nanda R, Boulware D, Baz R, Portman D, Yu HM, Jim H, Johnstone PAS. Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma. Acta Oncol. 2020 Aug.59(8):983-987. Pubmedid: 32496846. Pmcid: PMC7771243.
  • Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 Aug.19(8):1598-1612. Pubmedid: 32499299. Pmcid: PMC7665848.
  • Brohl AS, Sondak VK. Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma. J Clin Oncol. 2020 Aug.38(22):2471-2475. Pubmedid: 32530767.
  • Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug.7(8):e601-e612. Pubmedid: 32563283. Pmcid: PMC7302757.
  • McClure E, Carr MJ, Zager JS. The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. Expert Rev Anticancer Ther. 2020 Aug.20(8):687-701. Pubmedid: 32667249.
  • Hanna CB, Mudaliar D, John K, Allen CL, Sun L, Hawkinson JE, Schönbrunn E, Georg GI, Jensen JT. Development of WEE2 kinase inhibitors as novel non-hormonal female contraceptives that target meiosis†. Biol Reprod. 2020 Aug.103(2):368-377. Pubmedid: 32667031. Pmcid: PMC7401407.
  • Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, OʼDorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 Aug.49(7):863-881. Pubmedid: 32675783.
  • Moore CE, Monforte H, Teer JK, Zhang Y, Yoder S, Brohl AS, Reed D. TRIM28 congenital predisposition to Wilms' tumor: novel mutations and presentation in a sibling pair. Cold Spring Harb Mol Case Stud. 2020 Aug.6(4). Pubmedid: 32699065. Pmcid: PMC7476416.
  • Pointer DT, Roife D, Powers BD, Murimwa G, Elessawy S, Thompson ZJ, Schell MJ, Hodul PJ, Pimiento JM, Fleming JB, Malafa MP. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. BMC Cancer. 2020 Aug.20(1):750. Pubmedid: 32782024. Pmcid: PMC7422564.
  • Payne KK, Mine JA, Biswas S, Chaurio RA, Perales-Puchalt A, Anadon CM, Costich TL, Harro CM, Walrath J, Ming Q, Tcyganov E, Buras AL, Rigolizzo KE, Mandal G, Lajoie J, Ophir M, Tchou J, Marchion D, Luca VC, Bobrowicz P, McLaughlin B, Eskiocak U, Schmidt M, Cubillos-Ruiz JR, Rodriguez PC, Gabrilovich DI, Conejo-Garcia JR. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells. Science. 2020 Aug.369(6506):942-949. Pubmedid: 32820120. Pmcid: PMC7646930.
  • Kuykendall AT, Horvat NP, Pandey G, Komrokji R, Reuther GW. Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers (Basel). 2020 Aug.12(8). Pubmedid: 32823910. Pmcid: PMC7464183.
  • Premi S. Role of Melanin Chemiexcitation in Melanoma Progression and Drug Resistance. Front Oncol. 2020 Aug.10:1305. Pubmedid: 32850409. Pmcid: PMC7425655.
  • Fang B, Izumi V, Rix LLR, Welsh E, Pike I, Reuther GW, Haura EB, Rix U, Koomen JM. Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator Approach. Proteomics. 2020 Dec.20(24):e2000116. Pubmedid: 32865326. Pmcid: PMC7771371.